

11-16-00

A

JC715 U.S. PTO
11/15/00

BAKER BOTTS LLP

30 ROCKEFELLER PLAZA
44TH FLOOR
NEW YORK, NEW YORK
10112-4498
212 705 5000
FAX 212 705 5020

AUSTIN
BAKU
DALLAS
HOUSTON
LONDON
MOSCOW
NEW YORK
WASHINGTON

Appln. Trans.
PATENT

UTILITY PATENT
APPLICATION
TRANSMITTAL

(Only for new nonprovisional
applications under 37 CFR 1.53(b))

Attorney Docket No. A32000-A-072667.0172

First Named Inventor YANNICK BATARD

Express Mail Label No. EK938097140US

Total Pages

JC659 U.S. PTO
09/11/3794
11/15/00

November 15, 2000

BY EXPRESS MAIL - Label No. DEK938097140US

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

Sir:

Enclosed herewith for filing is a patent application of YANNICK BATARD, FRANCIS DURST, MICHEL SCHALK and DANIELE WERCK-REICHHART entitled RECODING OF DNA SEQUENCES PERMITTING EXPRESSION IN YEAST AND OBTAINED TRANSFORMED YEAST

which includes:

☒ Specification 42 Total Pages
☒ Claims 6 Total Pages
☒ Abstract 1 Total Pages
☐ Drawing(s) Total Sheets
 formal
 informal

☒ Combined Declaration and Power of Attorney 3 Total Pages
☐ Newly executed (original or copy)
☒ Copy from a prior application
(for continuation/divisional only - **must be filed to avoid surcharge for late filing**)

If a continuing application, check appropriate box:

☒ Continuation ☐ Divisional ☐ Continuation-In-Part (CIP)
of prior application No. 09/158,767

☒ Amend the specification by inserting, before the first line, the following sentence:

"This is a ☒ continuation ☐ divisional ☐ continuation-in-part
of copending application Serial No. 09/158,767 filed September 23, 1998."

Attorney Docket No. A32000-A-072667.0172

- ☒ An Assignment of the invention to RHONE-POULENC AGRO.
☐ is attached. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
☐ will follow.
☒ has been filed in the prior application

- ☐ Small Entity Statement(s) **ENCLOSED**.
☐ Small Entity Statement filed in prior application. Status still proper and desired.

- ☒ Information Disclosure Statement (IDS) PTO-1449
☒ Copies of IDS Citations.

☒ Preliminary Amendment

☒ Return Receipt Postcard

☒ Other Letter Under 37 C.F.R. 1.821(e)

☐ Cancel in this application original claims _ of the prior application before calculating the filing fee.

The filing fee has been calculated as shown below:

FOR	(Col. 1) <u>No. Filed</u>			(Col. 2) <u>No. Extra</u>			Small Entity <u>Rate</u>	<u>Fee</u>	OR	Other Than A Small Entity <u>Rate</u>	<u>Fee</u>
Basic Fee											\$710.00
Total Claims	28	-20	=	8	x	9 =	\$0.00		x	18 =	\$144.00
Ind. Claims	2	-3	=	0	x	40 =	\$0.00		x	80 =	\$0.00
Multiple Dependent Claim						+ 135 =				+ 270 =	
						Total	<u>\$0.00</u>				<u>\$854.00</u>

* If the difference in Col. 1 is less than zero, enter "0" in Col. 2.

Fee Payment Being Made:

☒ Enclosed

☒ Basic filing fee \$854.00

☐ Recording Assignment \$0.00
 [\$40.00; 37 CFR 1.21(h)]

Total Fees Enclosed \$854.00

☒ A check in the amount of \$854.00 to cover filing fee is enclosed.

Appln. Trans.
PATENT

Attorney Docket No. A32000-A-072667.0172

Priority

[X] Priority of application Country FRANCE, Appln. No. 9712094 filed September 24, 1997 is claimed under 35 U.S.C. 119.


[X] Certified Copy of Priority Document(s) Country FRANCE, Appln No. 9712094, filed September 24, 1997.

☐ is/are attached ☐ will follow ☒ has been filed in the parent application S/N 09/158,767.

[X] The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR 1.16, 1.17, and 1.21(h) associated with this communication or credit any overpayment to Deposit Account No. 02-4377. Two copies of this sheet are enclosed.

BAKER BOTTS L.L.P.

By



Janet M. MacLeod

PTO Registration No. 35,263

Enclosures

FILE NO. A32000-A-072667.0172

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Yannick Batard et al.
Serial No. : NOT YET ASSIGNED Examiner:
Filed : HEREWITH Group Art Unit:
For : RECODING OF DNA SEQUENCES
PERMITTING EXPRESSION IN YEAST
AND OBTAINED TRANSFORMED YEAST

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

Please amend the above-identified application as follows:

IN THE SPECIFICATION:

Page 12, lines 15-16, delete "(sequence identifier No. 1)" and substitute
therefor --of SEQ ID NO: 1 (which encodes the amino acid sequence of SEQ ID NO:
15)--.

Page 14, line 11, after "No. 7" insert --(which encodes the amino acid sequence of SEQ. ID NO: 16)--.

Page 14, line 11, after "No. 8" insert --(which encodes the amino acid sequence of SEQ. ID NO: 17)--.

Page 14, line 11, after "No. 9" insert --(which encodes the amino acid sequence of SEQ ID NO: 18)--.

Page 18, line 2, after "No. 10" insert --, which encodes the amino acid sequence of SEQ ID NO: 19--.

Page 18, line 14, after "No. 14" insert --, which encodes the amino acid sequence of SEQ ID NO: 20--.

Please delete pages 20-42 and renumber Pages 43-48 as pages 20-25.

After page 48, please insert the attached substitute sequence listing.

IN THE CLAIMS:

Claim 5, lines 1-2, delete "one of Claims 1 to 4" and substitute therefor --claim 1--.

Claim 7, lines 1-2, delete "one of claims 1 to 7" and substitute therefor --claim 1--.

PATENT

Claim 11, lines 1-2, delete "one of claims 9 or 10" and substitute therefor

--claim 9--.

Claims 12, lines 1-2, delete "one of claims 1 to 11" and substitute therefor

--claim 1--.

Claim 13, lines 1-2, delete "one of claims 1 to 12" and substitute therefor

--claim 1--.

Claim 15, lines 1-2, delete "one of claims 1 to 14" and substitute therefor

--claim 1--.

Claim 18, lines 1-2, delete "one of claims 1 to 17" and substitute therefor

--claim 1--.

Claim 22, line 2, delete "one of claims 1 to 21" and substitute therefor

--claim 1--.

Claim 27, line 5, delete "according to claim 23".

Claim 27, line 6, delete "one of claims 1 to 21" and substitute therefor

--claim 1--.

Claim 28, line 6, delete "according to claim 23".


Claim 28, lines 7-8, delete "one of claims 1 to 21" and substitute therefor

--claim 1--.

REMARKS

The foregoing amendments are necessary to conform the specification to the Sequence Listing and to remove multiple dependencies. No new matter has been introduced by the foregoing amendments.

Respectfully submitted,


Louis S. Sorell
Patent Office Reg. No. 32,439

Attorney for Applicants
(212) 408-2620

Janet M. MacLeod
Patent Office Reg. No. 35,263

Attorney for Applicants
(212) 408-2597

The recoding of DNA sequences to enable them to be
expressed in yeasts, and the transformed yeasts
obtained

The present invention relates to the recoding
5 of DNA sequences which encode proteins which contain
regions having a high content of codons which are
poorly translated by yeasts, in particular which encode
proteins of plant origin, such as the P450 cytochromes
of plant origin, and to their expression in yeasts.

10 It is known that certain sequences encoding
proteins of interest, in particular proteins of plant
origin, are not readily translated in yeasts. This
applies, in particular, to proteins which possess
regions having a high content of codons which are
15 poorly suited to yeasts, in particular leucine codons,
such as some P450 cytochromes of plant origin. Some
systems which have been developed for improving the
expression of P450 cytochromes of animal or plant
origin in yeasts, such as those described by Pompon et
20 al. (*Methods Enzymol.*, 272, 1996, 51-64; WO 97/10344),
have turned out to be unsuitable for large numbers of
P450 cytochromes which encompass regions having a high
content of codons which are poorly suited to yeasts.

The P450 cytochromes constitute a superfamily
25 of membrane enzymes of the monooxygenase type which are
able to oxidize a large family of generally hydrophobic
substrates. The reactions are most frequently
characterized by the oxidation of C-H or C=C bonds, and

00577 46467260

of heteroatoms, and, more rarely, by the reduction of
nitro groups or by dehalogenation. More specifically,
these enzymes are involved in the metabolism of
xenobiotic substances and drugs and in the biosynthesis
5 of secondary metabolites in plants, some of which have
organoleptic or pharmacodynamic properties.

As a consequence, the P450 cytochromes are
used, in particular, in:

- the *in vitro* diagnosis of the formation of
10 toxic or mutagenic metabolites (molecules of natural
origin, pollutants, drugs, pesticides, etc.), making it
possible, in particular, to develop novel active
molecules (pharmaceutical, agrochemistry),
- the identification and destruction of
15 molecules which are toxic for, or pollute, the
environment,
- the enzymic synthesis of novel molecules.

The search for heterologous expression of
P450 cytochromes by host cells, more specifically
20 yeasts, is therefore important for obtaining controlled
production of this enzyme in large quantity, either for
isolating it and using it in the above-listed
processes, or for using the transformed cells directly
for the said processes without previously isolating the
25 enzyme.

The present invention provides a solution to
the abovementioned problem, enabling proteins which
contain regions having a high content of codons which

are poorly suited to yeasts, in particular P450 cytochromes of plant origin, to be expressed in yeasts.

The present invention therefore relates to a DNA sequence, in particular a cDNA sequence, which
5 encodes a protein of interest which contains regions having a high content of codons which are poorly suited to yeasts, characterized in that a sufficient number of codons which are poorly suited to yeasts is replaced with corresponding codons which are well-suited to
10 yeasts in the said regions having a high content of codons which are poorly suited to yeasts.

Within the meaning of the present invention, "codons which are poorly suited to yeasts" are understood as being codons whose frequency of use by
15 yeasts is less than or equal to approximately 13 per 1000, preferably less than or equal to approximately 12 per 1000, more preferably less than or equal to approximately 10 per 1000. The frequency at which codons are used by yeasts, more specifically by
20 *S. cerevisiae*, is described, in particular, in "Codon usage data base from Yasukazu Nakamura" (<http://www.dna.affrc.go.jp/~nakamura/codon.html>). This applies, in particular, to codons CTC, CTG and CTT, which encode leucine, to codons CGG, CGC, CGA, CGT and
25 AGG, which encode arginine, to codons GCG and GCC, which encode alanine, to codons GGG, GGC and GGA, which encode glycine, and to codons CCG and CCC, which encode proline. The codons which are poorly suited to yeasts

in accordance with the invention are, more specifically, codons CTC and CTG, which encode leucine, CCG, CGC, CGA, CGT and AGG, which encode arginine, codons GCG and GCC, which encode alanine, GGG and GGC, which encode glycine, and codons CCG and CCC, which
5 encode proline.

Within the meaning of the present invention, "corresponding codons which are well-suited to yeasts" are understood as being the codons which correspond to
10 the codons which are poorly suited to yeasts and which encode the same amino acids, and whose frequency of use by yeasts is greater than 15 per 1000, preferably greater than or equal to 18 per 1000, more preferably greater than or equal to 20 per 1000. This applies, in
15 particular, to codons TTG and TTA, preferably TTG, which encode leucine, to codon AGA, which encodes arginine, to codons GCT and GCA, preferably GCT, which encode alanine, to codon GGT, which encodes glycine, and to codon CCA, which encodes proline.

20 Within the meaning of the present invention, "region having a high content of codons which are poorly suited to yeasts" is understood as being any region of the DNA sequence which contains at least 2 poorly suited codons among 10 consecutive codons, with
25 it being possible for the two codons to be adjacent or separated by up to 8 other codons. According to one preferred embodiment of the invention, the regions having a high content of poorly suited codons contain

2, 3, 4, 5 or 6 poorly suited codons per 10 consecutive codons, or contain at least 2 or 3 adjacent poorly suited codons.

Within the meaning of the present invention,
5 "sufficient number of codons" is understood as being the number of codons which it is necessary and sufficient to replace in order to observe a substantial improvement in their expression in yeasts.

Advantageously, at least 50% of the codons which are
10 poorly suited to yeasts in the high-content region under consideration are replaced with well-suited codons. Preferably, at least 75% of the poorly suited codons of the said region are replaced, with 100% of the poorly suited codons more preferably being
15 replaced.

Within the meaning of the present invention,
"substantial improvement" is understood as being either a detectable expression when no expression of the reference sequence is observed, or an increase in
20 expression as compared with the level at which the reference sequence is expressed.

Within the meaning of the present invention,
"reference sequence" designates any sequence which encodes a protein of interest and which is modified in
25 accordance with the invention in order to promote its expression in yeasts.

The present invention is particularly well suited to DNA sequences, in particular cDNA sequences,

which encode proteins of interest which contain regions having a high content of leucine and in which a sufficient number of CTC codons encoding leucine in the said region having a high content of leucine is replaced with TTG and/or TTA codons, or in which a sufficient number of CTC and CTG codons encoding leucine in the said region having a high content of leucine is replaced with TTG and/or TTA codons, preferably with a TTG codon.

10 Within the meaning of the present invention, "region having a high content of leucine" is understood as being a region which contains at least 2 leucines among 10 consecutive amino acids in the protein of interest, with it being possible for the two leucines to be adjacent or separated by up to 8 other amino acids. According to one preferred embodiment of the invention, the regions having a high content of leucine contain 2, 3, 4, 5 or 6 leucines per 10 consecutive amino acids, or contain at least 2 or 3 adjacent leucines.

 According to a preferred embodiment of the invention, at least 50% of the CTC or CTC and CTG codons of the region having a high content of leucine are replaced with TTG or TTA codons, with at least 75% of the CTC or CTC and CTG codons of the said region preferably being replaced, and 100% of the CTC or CTC and CTG codons more preferably being replaced.

 Advantageously, the present invention is

particularly suitable for DNA sequences whose general content of poorly suited codons is at least 20%, more preferably at least 30%, as compared with the total number of codons in the reference sequence.

5 Advantageously, when the reference sequence contains at least one 5' region having a high content of poorly suited codons, the recoding of this 5' region alone makes it possible to obtain a substantial improvement in the expression of the protein of
10 interest in yeasts. The length of the 5' region to be recoded in accordance with the invention will vary depending on the length of the region having a high content of poorly suited codons. This length will advantageously be at least four codons, in particular
15 when this region contains at least two adjacent poor codons, up to approximately 40 codons or more.

 However, it is not necessary, according to the invention, to recode all the reference sequence, but only the regions having a high content of poor
20 codons, in particular the 5' region on its own, in order to obtain a substantial improvement in the expression of the protein of interest in yeasts.

 Advantageously, the DNA sequence encoding a protein of interest is an isolated DNA sequence of
25 natural origin, in particular of plant origin. The invention is particularly advantageous for sequences which originate from monocotyledonous or dicotyledonous plants, preferably monocotyledonous plants, in

00577 4626260

particular of the gramineae family, such as wheat, barley, oats, rice, maize, sorghum, cane sugar, etc.

According to a preferred embodiment of the invention, the DNA sequence encodes an enzyme, in particular a cytochrome P450, which is preferably of plant origin. These P450 cytochromes exhibit a high content of poorly suited codons, in particular encoding leucine, in their N-terminal region; it is in the 5'-terminal coding region that the poorly suited codons are replaced.

The present invention also relates to a chimeric gene which comprises a DNA sequence which has been modified as above and heterologous 5' and 3' regulatory elements which are able to function in a yeast, that is to say which are able to control the expression of the protein of interest in the yeast. Such regulatory elements are well known to the skilled person and are described, in particular, by Rozman et al. (Genomics, 38, 1996, 371-381) and by Nacken et al. (Gene, 175, 1996, 253-260, *Probing the limits of expression levels by varying promoter strength and plasmid copy number in Saccharomyces cerevisiae*).

The present invention also relates to a vector for transforming yeasts which contains at least one chimeric gene as described above. It also relates to a process for transforming yeasts with the said vector and to the transformed yeasts which are obtained. It finally relates to a process for producing

00577" 46267260

a heterologous protein of interest in a transformed yeast, with the sequence which encodes the said protein of interest being such as defined above.

The process for producing a heterologous protein of interest in a transformed yeast comprises the steps of:

- a) transforming a yeast with a vector which is able to replicate in yeasts and which contains a modified DNA sequence as defined above and heterologous 5' and 3' regulatory elements which are able to function in a yeast,
- b) culturing the transformed yeast, and
- c) extracting the protein of interest from the yeast culture.

When the protein of interest is an enzyme which is suitable for transforming a substrate, such as a cytochrome P450, the enzyme which has been extracted from the yeast culture is then used for catalysing the transformation of the said substrate.

However, the catalysis can be carried out, without requiring the extraction of the yeast, by culturing the transformed yeast in the presence of the said substrate.

The present invention also relates, therefore, to a process for transforming a substrate by enzymic catalysis using an enzyme which is expressed in a yeast, which process comprises the steps of

- a) culturing the yeast which has been

transformed in accordance with the invention in the presence of the substrate to be transformed, then

b) recovering the transformed substrate from the yeast culture.

5 When the yeast has been transformed for expressing a cytochrome P450, the reaction which is catalysed by the enzyme is an oxidation reaction, more specifically a reaction in which C-H or C=C bonds are oxidized.

10 The techniques for transforming and culturing yeasts are known to the skilled person, and are described, for example, in *Methods in Enzymology* (Vol. 194, 1991).

15 Yeasts which are of use in accordance with the invention are selected, in particular, from the genera *Saccharomyces*, *Kluyveromyces*, *Hansenula*, *Pichia* and *Yarrowia*. Advantageously, the yeast belongs to the *Saccharomyces* genus, and is in particular *S. cerevisiae*.

20 Other characteristics of the invention will become apparent in the light of the examples which follow.

Example 1: Production of a wheat cDNA gene library, and identification of the CYP73A17 sequence

25 The wheat cytochrome P450 CYP73A17 sequence was obtained by screening a young wheat plantlet (shoots and roots without the caryopses) cDNA library which was constructed in the vector λ -ZapII (Stratagene) in accordance with the supplier's

instructions.

1. Production of the cDNA library

Triticum aestivum (L. cv. Darius) seeds which had been coated with cloquintocet-mexyl (0.1% per dry weight of seed) are cultured in plastic boxes on two layers of damp gauze until shoots having a size of 3 to 5 mm are obtained. The water in the boxes is then replaced with a solution of 4 mM sodium phenobarbital and the wheat is cultured until the shoots are approximately 1 cm in size.

The cDNA library is constructed in the λ -ZapII (Stratagene) vector, in accordance with the supplier's protocol and instructions, using 5 μ g of poly(A)⁺ RNA (Lesot, A., Benveniste, I., Hasenfratz, M.P., Durst, F. (1990) Induction of NADPH cytochrome P450(c) reductase in wounded tissues from *Helianthus tuberosus* tubers. Plant Cell Physiol., 31, 1177-1182) which were isolated from the treated roots and shoots.

2. Screening the cDNA library

5 \times 10⁵ lysis plaques from the previously obtained λ -ZapII library are screened using a probe which corresponds to the complete coding sequence of *Helianthus tuberosus* CYP73A1, and which has been labelled by random priming with [α -³²P]dCTP. The filters are prehybridized and hybridized at low stringency at 55°C in accordance with the standard protocols. The membranes are washed twice for 10 minutes with 2 \times SSC, 0.1% SDS, and once for 10 minutes with 0.2 \times SSC, 0.1%

SDS at ambient temperature, then twice for 30 minutes with 0.2 × SSC, 0.1% SDS at 45°C. The inserts of the positive lysis plaques are analysed by PCR (polymerization chain reaction) and hybridization in order to determine their size. The clones containing inserts which hybridize with CYP73A1 under the above-described conditions and which are greater than 1.5 kbp in size are rescreened before excision of the pBluescript plasmid in accordance with the supplier's (Stratagene) protocol and sequencing using the Ready Reaction Dye Deoxy Terminator Cycle prism technique developed by Applied Biosystems Inc. A full length clone is then identified by alignment with CYP73A1.

The wheat cytochrome P450 CYP73A17 which is encoded by the isolated sequence (sequence identifier No. 1) exhibits 76.2% identity with the *Helianthus tuberosus* CYP73A1.

Example 2: Alterations to the sequence encoding the wheat cytochrome P450 CYP73A17

Contrary to the situation with regard to *Helianthus tuberosus* CYP73A1, which can be expressed in yeasts (Urban et al., 1994), repeated attempts to express wheat CYP73A17 in yeasts using the same customary techniques proved to be fruitless when the nucleotide sequence was not altered at the time it was inserted into the expression vector (verification by sequencing). No protein is detected by spectrophotometry or by immunoblotting, just as no

0974394-11500
005777-46237260

enzymic activity is detectable in the microsomes of transformed and induced yeast.

1. Alteration of the coding sequence

The sequence encoding wheat CYP73A17 (SEQ. ID No. 1) was therefore altered, in three different ways, by PCR-induced mutagenesis, as follows:

The *Bam*HI and *Eco*RI restriction sites were respectively introduced by PCR just upstream of the ATG codon and just downstream of the stop codon of the CYP73A17 coding sequence (source, origin) using the sense and reverse primers described below, with the restriction sites being *Bam*HI in the case of the sense primers Rec1 (SEQ ID No. 3), Rec2 (SEQ ID No. 4) and Rec3 (SEQ ID No. 5), and *Eco*RI in the case of the reverse primer (SEQ ID No. 6).

A primer, represented by SEQ ID No. 2, was also employed for enabling yeasts to be transformed with the unmodified (native) sequence encoding wheat CYP73A17.

The five primers described above were obtained from Eurogentech, and were synthesized and purified in accordance with customary methods.

For each alteration using the four different sense primers, the mode of operation is as follows:

The reaction mixture (20 mM Tris-HCl, pH 8.75, 10 mM KCl, 10 mM (NH₄)₂SO₄, 2 mM MgSO₄, 0.1% Triton X100, 0.1 mg/ml BSA, 5% (v/v) DMSO, 300 μM dNTP, 20 pmoles of each primer, 150 ng of template, total

volume 50 μ l) is preheated at 94°C for 2 minutes before adding 5 units of Pfu DNA polymerase (Stratagene).

After 2 minutes at 94°C, 30 amplification cycles are carried out as follows: 1 minute of denaturation at 94°C, 2 minutes of hybridization at 55°C, 2 minutes of extension at 72°C. The reaction is completed by 10 minutes of extension at 72°C.

For each primer, a sequence is obtained which is derived from sequence ID No. 1, and which is represented, in the case of the altered coding sequences, by the sequences ID No. 7, No. 8 and No. 9. The 5' ends of the sequences obtained using the four abovementioned sense primers are depicted below, with the *Bam*HI restriction site being shown in italics:

native:	ATATATGGATCC ATG GAC GTC CTC CTC CTG GAG AAG GCC
Rec 1	ATATATGGATCC ATG GAT GTT TTG TTG TTG GAG AAG GCC
Rec 2	ATATATGGATCC ATG GAT GTT TTG TTG TTG GAA AAA GCT
Rec 3	ATATATGGATCC ATG GAT GTT TTG TTG TTG GAA AAA GCT
Protein:	met asp val leu leu leu glu lys ala

CTC CTG GGC CTC TTC GCC GCG GCG GTG CTG GCC ATC GCC GTC GCC
 CTC CTG GGC CTC TTC GCC GCG GCG GTG CTG GCC ATC GCC GTC GCC
 TTG TTG GGT TTG TTC GCC GCG GCG GTG CTG GCC ATC GCC GTC GCC
 TTG TTG GGT TTG TTT GCT GCT GCT GTT TTG GCT ATT GCT GTT GCT
 leu leu gly leu phe ala ala ala val leu ala ile ala val ala

AAG CTC ACC GGC AAG CGC TTC CGC CTC CCC CCT GGC CCC TCC GGC
 AAG CTC ACC GGC AAG CGC TTC CGC CTC CCC CCT GGC CCC TCC GGC
 AAG CTC ACC GGC AAG CGC TTC CGC CTC CCC CCT GGC CCC TCC GGC
 AAA TTG ACT GGT AAA AGA TTT AGA TTG CCA CCA GGT CCA TCC GGC
 lys leu thr gly lys arg phe arg leu pro pro gly pro ser gly

GCC CCC ATC GTC
 GCC CCC ATC GTC
 GCC CCC ATC GTC
 GCC CCC ATC GTC
 ala pro ile val

2. Transforming the yeasts

After having been digested with the
 5 restriction enzymes *Bam*HI and *Eco*RI, the four above-
 described altered coding sequences are integrated into
 the vector pYeDP60, which is described by Pompon et al.
 (*Methods Enzymol*, 272, 1996, 51-64; WO 97/10344), the
 content of which is hereby incorporated by reference
 10 with regard to the plasmid, the method of insertion
 into the plasmid, and the method of transforming and
 growing the yeasts, in particular using the
Saccharomyces cerevisiae yeast strains W(R), WAT21 and
 WAT11. The method for transforming and growing yeasts
 15 is also described by Pompon et al. and by Urban et al.

(*Eur. J. Biochem*, 222, 1994, page 844, 2nd column,
"Yeast transformation and cell culture").

4 transformed yeast strains, designated:
W73A17(native), W73A17(Rec1), W73A17(Rec2) and
5 W73A17(Rec3), are obtained.

Example 3: Expression of CYP73A17 in the altered yeasts

The previously obtained transformed yeasts
are cultured, in accordance with the method described
by Urban et al. (*Eur. J. Biochem.*, 222, 1994, page 844,
10 2nd column, "Yeast transformation and cell culture"),
in 50 ml of SGI medium at 30°C for 72 h. The cells are
recovered by centrifuging at 8000 g for 10 minutes,
washed with 25 ml of YPI medium, recentrifuged, and
then resuspended in 250 ml of YPI medium. The cells are
15 induced with galactose for 14-16 h, while being shaken
at 160 rpm, until the cell density reaches 10^8 cells per
ml. The microsomes are then prepared using the method
described by Pierrel et al. (*Eur. J. Biochem.*, 224,
1994, 835-844).

20 The expression of CYP73A17 achieved in the
case of the four strains is quantified by differential
spectrophotometry using the method described by Omura
and Sato (*J. Biol. Chem.*, 177, 678-693). It is
proportional to the number of poorly suited codons
25 which have been altered.

The microsomal enzymic activity is measured
using the method described by Durst F., Benveniste I.,
Schalk M. and Werck-Reichhart D. (1996) Cinnamic acid

hydroxylase activity in plant microsomes. Methods Enzymol. 272, 259-268. The results obtained after transforming WAT21 are recorded in the Table below. The activity is expressed as cinnamate 4-hydroxylase activity. The percentage additional activity (rounded values) illustrates the extent of the leap in activity which is observed after the poorly suited codons have been altered.

Strain	Activity pmol/min/ μ g of protein	% additional activity
W73A17 native	0.64	-
W73A17 Rec1	2.84	+340
W73A17 Rec2	4.92	+670
W73A17 Rec3	8.90	+1300

These results relating to the increase in enzymic activity confirm those relating to the increase in the expression of the protein in the yeasts. They demonstrate that alteration of the 5' end alone, even when limited (Rec1), is sufficient to obtain a very substantial improvement in the production of the enzyme by the yeast and in its enzymic activity.

Example 4: Expression of wheat CYP86A5 in the altered yeasts

The sequence encoding wheat cytochrome P450

CYP86A5, which is depicted by sequence identifier No. 10 (SEQ ID No. 10), was isolated from the wheat cDNA library described in Example 1 using the same method of operation as described for the CYP73A17 sequence and
5 employing the complete coding sequence of *Arabidopsis thaliana* CYP86A1 as the probe. This wheat CYP86A5 sequence was altered, in accordance with the mode of operation of Example 2, using the two oligonucleotides depicted by the sequences ID No. 12 and 13 (SEQ ID
10 No. 12 and SEQ ID No. 13) as sense and reverse primers, respectively, in order to obtain the coding sequence which is altered in accordance with the invention and which is depicted by sequence identifier No. 14 (SEQ ID No. 14).

15 A primer depicted by SEQ ID No. 11 was also used to enable yeasts to be transformed with the sequence encoding unmodified (native) wheat CYP86A5.

 The yeasts are transformed with this new coding sequence and the expression is quantified by
20 differential spectrophotometry in accordance with the mode of operation described in Example 2. While the natural sequence of wheat CYP86A5 is not expressed in a detectable manner, there is substantial expression in the transformed yeasts of the sequence which has been
25 modified in accordance with the invention.

 The above-described examples demonstrate unambiguously that the expression in yeasts of DNA sequences which possess a 5' region having a high

5

CCTCAGCACGG CAACACATAC ACAGGAGCCA CACACCGCAC CTACCCCG ATG GAC GTC Met Asp Val 1																57
CTC Leu	CTC Leu 5	CTG Leu	GAG Glu	AAG Lys	GCC Ala	CTC Leu 10	CTG Leu	GGC Gly	CTC Leu	TTC Phe	GCC Ala 15	GCG Ala	GCG Ala	GTG Val	CTG Leu	105
GCC Ala 20	ATC Ile	GCC Ala	GTC Val	GCC Ala 25	AAG Lys	CTC Leu	ACC Thr	GGC Gly	AAG Lys	CGC Arg 30	TTC Phe	CGC Arg	CTC Leu	CCC Pro	CCT Pro 35	153
GGC Gly	CCC Pro	TCC Ser	GGC Gly	GCC Ala 40	CCC Pro	ATC Ile	GTC Val	GGC Gly	AAC Asn 45	TGG Trp	CTG Leu	CAG Gln	GTC Val	GGC Gly 50	GAC Asp	201
GAC Asp	CTC Leu	AAC Asn	CAC His 55	CGC Arg	AAC Asn	CTG Leu	ATG Met	GGC Gly 60	CTG Leu	GCC Ala	AAG Lys	CGG Arg	TTC Phe 65	GGC Gly	GAG Glu	249
GTG Val	TTC Phe	CTC Leu 70	CTC Leu	CGC Arg	ATG Met	GGC Gly 75	GTC Val	CGC Arg	AAC Asn	CTG Leu	GTG Val	GTC Val 80	GTC Val	TCC Ser	AGC Ser	297
CCC Pro 85	GAG Glu	CTC Leu	GCC Ala	AAG Lys	GAG Glu 90	GTC Val	CTC Leu	CAC His	ACC Thr	CAG Gln	GGC Gly 95	GTC Val	GAG Glu	TTC Phe	GGC Gly	345
TCC Ser 100	CGC Arg	ACC Thr	CGC Arg	AAC Asn	GTC Val 105	GTC Val	TTC Phe	GAC Asp	ATC Ile	Phe 110	ACC Thr	GGC Gly	AAG Lys	GGA Gly 115	CAG Gln	393
GAC Asp	ATG Met	GTG Val	TTC Phe	ACG Thr 120	GTG Val	TAC Tyr	GGC Gly	GAC Asp	CAC His 125	TGG Trp	CGC Arg	AAG Lys	ATG Met	CGG Arg 130	CGG Arg	441
ATC Ile	ATG Met	ACG Thr	GTG Val 135	CCC Pro	TTC Phe	TTC Phe	ACC Thr	AAC Asn 140	AAG Lys	GTG Val	GTG Val	GCG Ala	CAG Gln 145	AAC Asn	CGC Arg	489
GTG Val	GGG Gly	TGG Trp 150	GAG Glu	GAG Glu	GAG Glu	GCC Ala	CGG Arg 155	CTG Leu	GTG Val	GTG Val	GAG Glu	GAC Asp 160	CTC Leu	AAG Lys	GCC Ala	537

GAC Asp 165	CCG Pro	CCG Ala	GCG Ala	GCG Ala	ACG Thr	GCG Ala 170	GGC Gly	GTG Val	GTG Val	GTG Val	CGC Arg 175	CGC Arg	AGG Arg	CTG Leu	CAG Gln	585
CTC Leu 180	ATG Met	ATG Met	TAC Tyr	AAC Asn	GAC Asp 185	ATG Met	TTC Phe	CGC Arg	ATC Ile	ATG Met 190	TTC Phe	GAC Asp	CGC Arg	CGG Arg	TTC Phe 195	633
GAG Glu	AGC Ser	GTG Val	GCC Ala 200	GAC Asp	CCG Pro	CTC Leu	TTC Phe	AAC Asn	CAG Gln 205	CTC Leu	AAG Lys	GCG Ala	CTC Leu	AAC Asn 210	GCC Ala	681
GAG Glu	CGC Arg	AGC Ser	ATC Ile 215	CTC Leu	TCC Ser	CAG Gln	AGC Ser	TTC Phe 220	GAC Asp	TAC Tyr	AAC Asn	TAC Tyr	GCG Gly 225	GAC Asp	TTC Phe	729
ATC Ile	CCC Pro	GTC Val 230	CTC Leu	CGC Arg	CCC Pro	TTC Phe	CTC Leu 235	CGC Arg	CGC Arg	TAC Tyr	CTC Leu	AAC Asn 240	CGC Arg	TGC Cys	ACC Thr	777
AAC Asn 245	CTC Leu	AAG Lys	ACC Thr	AAG Lys	CGG Arg	ATG Met 250	AAG Lys	GTG Val	TTC Phe	GAG Glu	GAC Asp 255	CAC His	TTC Phe	GTC Val	CAG Gln	825
CAG Gln 260	CGC Arg	AAG Lys	GAG Glu	GCG Ala 265	GAG Glu	AAG Lys	ACG Thr	GGT Gly	GAG Glu 270	ATC Ile	AGG Arg	TGC Cys	GCC Ala	ATG Met 275		873
GAC Asp	CAC His	ATC Ile	CTG Leu 280	GAA Glu	GCC Ala	GAA Glu	AGG Arg	AAG Lys	GGC Gly 285	GAG Glu	ATC Ile	AAC Asn	CAC His	GAC Asp 290	AAC Asn	921
GTC Val	CTC Leu	TAC Tyr	ATC Ile 295	GTC Val	GAG Glu	AAC Asn	ATC Ile	AAC Asn 300	GTC Val	GCA Ala	GCC Ala	ATC Ile	GAG Glu 305	ACG Thr	ACG Thr	969
CTG Leu	TGG Trp 310	TCG Ser	ATC Ile	GAG Glu	TGG Trp	GGC Gly	CTC Leu 315	CGC Ala	GAG Glu	CTG Leu	GTG Val	AAC Asn 320	CAC His	CCG Pro	GAG Glu	1017
ATC Ile 325	CAG Gln	CAG Gln	AAG Lys	CTG Leu	CGC Arg	GAG Glu 330	GAG Glu	ATC Ile	GTC Val	GCC Ala	GTT Val 335	CTG Leu	GGC Gly	GCC Ala	GGC Gly	1065
GTG Val 340	GCG Ala	GTG Val	ACG Thr	GAG Glu	CCG Pro 345	GAC Asp	CTG Leu	GAG Glu	CGC Arg	CTC Leu 350	CCC Pro	TAC Tyr	CTG Leu	CAG Gln	TCC Ser 355	1113
GTG Val	GTG Val	AAG Lys	GAG Glu 360	ACG Thr	CTC Leu	CGC Arg	CTC Leu	CGC Arg	ATG Met 365	GCA Ala	ATC Ile	CCG Pro	CTC Leu	CTG Leu 370	GTG Val	1161
CCG Pro	CAC His	ATG Met	AAC Asn 375	CTC Leu	AGC Ser	GAC Asp	GCC Ala	AAG Lys 380	CTC Leu	GCC Ala	GGC Gly	TAC Tyr	GAC Asp 385	ATC Ile	CCC Pro	1209
GCC Ala	GAG Glu	TCC Ser 390	AAG Lys	ATC Ile	CTC Leu	GTC Val	AAC Asn 395	GCC Ala	TGG Trp	TTC Phe	CTC Leu	GCC Ala 400	AAC Asn	GAC Asp	CCC Pro	1257
AAG Lys 405	CGG Arg	TGG Trp	GTG Val	CGC Arg	GCC Ala	GAT Asp 410	GAG Glu	TTC Phe	AGG Arg	CCG Pro	GAG Glu 415	AGG Arg	TTC Phe	CTC Leu	GAG Glu	1305
GAG Glu 420	GAG Glu	AAG Lys	GCC Ala	GTC Val	GAG Glu 425	GCC Ala	CAC His	GGC Gly	AAC Asn	GAT Asp 430	TTC Phe	CGG Arg	TTC Phe	GTG Val	CCC Pro 435	1353

TTC GGC GTC GGC CGC CGG AGC TGC CCC GGG ATC ATC CTC GCG CTG CCC Phe Gly Val Gly Arg Arg Ser Cys Pro Gly Ile Ile Leu Ala Leu Pro 440 445 450	1401
ATC ATC GGC ATC ACG CTC GGA CGC CTG GTG CAG AAC TTC CAG CTG CTG Ile Ile Gly Ile Thr Leu Gly Arg Leu Val Gln Asn Phe Gln Leu Leu 455 460 465	1449
CCG CCG CCG GGG CAG GAC AAG ATC GAC ACC ACC GAG AAG CCC GGG CAG Pro Pro Pro Gly Gln Asp Lys Ile Asp Thr Thr Glu Lys Pro Gly Gln 470 475 480	1497
TTT ACC AAC CAG ATC CTC AAG CAC GCC ACC ATT GTC TGC AAG CCA CTC Phe Thr Asn Gln Ile Leu Lys His Ala Thr Ile Val Cys Lys Pro Leu 485 490 495	1545
GAG GCT TAACTGAATT GAGGTTTCGG TCATGGGCGC CCGCTGACGC GGGGAGATGG Glu Ala 500	1601
ATCTATGCAT GTGACTGTGT ATTTTGCCTT CTTTCTTTTT GGTGTTGTTT TTTGCAGTAG	1661
TAAGTTTAAT TTTTCTTTGG TGTGGCCTA TTTGTCTTCA TGTGAGGCGT CGTGTGTGTA	1721
ATTTCCATAT AGTTGGCAAT GTGATGTAAA ACTTGGCTCC AAAAAAAAAA AAAAAAACT	1781
CGAGACTCTT CTCTCTCTCT CTCTCTCTCC AGCCTCGGGT CTCTGCTGGC AAGGGAACTT	1841
GCATTACCCCT GTGTACGACG GCGCCATGTT CGTCCCTGAA GCACCCCTCCC TGCAGAGCTC	1901
CCAGGACAAC TTCGCTGCAT CTGCTGGTTT CAAGCGTCGA AGGAGAGAGT TTTGAATACC	1961
CGAAAGAATA TAGCGTTGGA CATATCTGTC AAACAGGGGA TCTTGCTGTG GGTCTCTTGG	2021
TGGGCCCAAAT CGCATAGACA ATCATTCAAA TGGATGGGTT CTTGCTGGT CGGTCAAAAA	2081
GTATATGTTG TAATTGTACG CTTTTTTTGG GTCTTGTTGC CAAAGATCAT GGTTATTGAG	2141
TTGTGAGCTC TGAGATAACA GGTGTGTGTA TAGTGAAATA AAGAGGAGCG TCGTCAACAC	2201
CATGTACTAT ATAGGCTTTG AAATTCCATT AAGATGCATC AGAAATCAAT GTTGGATTTG	2261

(2) INFORMATION FOR SEQ ID NO: 2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 38 base pairs
 - (B) TYPE: nucleotide
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "primer"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

ATATATGGAT CCATGGACGT CCTCCTCCTG GAGAAGGC

38

(2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 56 base pairs
 - (B) TYPE: nucleotide
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "primer"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

ATATATGGAT CCATGGATGT TTTGTTGTTG GAGAAGGCCCT TCCTGGGCCT CTCGC

56

(2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 71 base pairs
 - (B) TYPE: nucleotide
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

ATATATGGAT CCATGGATGT TTTGTTGTTG GAAAAAGCTT TGTGGGGTTT GTTCGCCGCG	60
GCGGTGCTGG C	71

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 143 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

ATATATGGAT CCATGGATGT TTTGTTGTTG GAAAAAGCTT TGTGGGGTTT GTTGTGCTGCT	60
GCTGTTTTGG CTATTGCTGT TGCTAAATTG ACTGTAATAA GATTAGATT GCCACCAGGT	120
CCATCCGGCG CCCCCATCGT CGG	143

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

39

(i) SEQUENCE CHARACTERISTICS:

(B) TYPE: nucleotide

(D) TOPOLOGY: linear

(ix) FEATURE:

(B) LOCATION: 1..1503

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

ATG Met 1	GAT Asp	GTT Val	TTG Leu	TTG Leu 5	GAG Leu	AAG Leu	GCC Glu	CCC Lys	CTC Ala	CTG Leu 10	GCC Gly	CTC Leu	TTC Phe	GCC Ala 15	GCG Ala		48
GCG Ala	GTG Val	CTG Leu	GCC Ala 20	ATC Ile	GCC Ala	GTC Val	GCC Ala	AAG Lys 25	CTC Leu	ACC Thr	GCG Gly	AAG Lys	CGC Arg 30	TTC Phe	CGC Arg		96
CTC Leu	CCC Pro	CCT Pro 35	GGC Gly	CCC Pro	TCC Ser	GGC Gly	GCC Ala 40	CCC Pro	ATC Ile	GTC Val	GGC Gly 45	AAC Asn	TGG Trp	CTG Leu	CAG Gln		144
GTC Val	GGC Gly 50	GAC Asp	GAC Asp	CTC Leu	AAC Asn	CAC His 55	CGC Arg	AAC Asn	CTG Leu	ATG Met	GGC Gly 60	CTG Leu	GCC Ala	AAG Lys	CGG Arg		192
TTC Phe 65	GGC Gly	GAG Glu	GTG Val	TTC Phe 70	CTC Leu	CTC Leu	CGC Arg	ATG Met	GGC Gly	GTC Val 75	CGC Arg	AAC Asn	CTG Leu	GTG Val 80	GTC Val		240
GTC Val	TCC Ser	AGC Ser	CCC Pro	GAG Glu 85	CTC Leu	GCC Ala	AAG Lys	GAG Glu	GTC Val 90	CTC Leu	CAC His	ACC Thr	CAG Gln	GGC Gly 95	GTC Val		288
GAG Glu	TTC Phe	GGC Gly	TCC Ser 100	CGC Arg	ACC Thr	CGC Arg	AAC Asn	GTC Val 105	GTC Val	TTC Phe	GAC Asp	ATC Ile	TTC Phe 110	ACC Thr	GGC Gly		336
AAG Lys	GGA Gly	CAG Gln 115	GAC Asp	ATG Met	GTG Val	TTC Phe	ACG Thr 120	GTG Val	TAC Tyr	GGC Gly	GAC Asp 125	CAC His	TGG Trp	CGC Arg	AAG Lys		384
ATG Met	CGG Arg 130	CGG Arg	ATC Ile	ATG Met	ACG Thr	GTG Val 135	CCC Pro	TTC Phe	TTC Phe	ACC Thr	AAC Asn 140	AAG Lys	GTG Val	GTG Val	GCG Ala		432
CAG Gln 145	AAC Asn	CGC Arg	GTG Val	GGG Gly 150	TGG Trp	GAG Glu	GAG Glu	GAG Glu	GCC Ala	CGG Arg 155	CTG Leu	GTG Val	GTG Val	GAG Glu 160	GAC Asp		480
CTC Leu	AAG Lys	GCC Ala	GAC Asp 165	CCG Pro	GCG Ala	GCG Ala	GCG Ala	ACG Thr 170	GCG Ala	GGC Gly	GTG Val	GTG Val	GTC Val	CGC Arg 175	CGC Arg		528
AGG Arg	CTG Leu	CAG Gln	CTC Leu 180	ATG Met	ATG Met	TAC Tyr	AAC Asn	GAC Asp 185	ATG Met	TTC Phe	CGC Arg	ATC Ile	ATG Met 190	TTC Phe	GAC Asp		576
CGC Arg	CGG Arg	TTC Phe 195	GAG Glu	AGC Ser	GTG Val	GCC Ala	GAC Asp 200	CCG Pro	CTC Leu	TTC Phe	AAC Asn	CAG Gln 205	CTC Leu	AAG Lys	GCG Ala		624
CTC Leu	AAC Asn 210	GCC Ala	GAG Glu	CGC Arg	AGC Ser	ATC Ile 215	CTC Leu	TCC Ser	CAG Gln	AGC Ser	TTC Phe 220	GAC Asp	TAC Tyr	AAC Asn	TAC Tyr		672
GCG Gly 225	GAC Asp	TTC Phe	ATC Ile	CCC Pro	GTG Val 230	CTC Leu	CGC Arg	CCC Pro	TTC Phe 235	CTC Leu	CGC Arg	CGC Arg	TAC Tyr	CTC Leu	AAC Asn 240		720

CGC	TCG	ACC	AAC	CTC	AAG	ACC	AAG	CGG	ATG	AAG	GTG	TTC	GAG	GAC	CAC	768
Arg	Cys	Thr	Asn	Leu	Lys	Thr	Lys	Arg	Met	Lys	Val	Phe	Glu	Asp	His	
				245				250						255		
TTC	GTC	CAG	CAG	CGC	AAG	GAG	GCG	TTG	GAG	AAG	ACG	GGT	GAG	ATC	AGG	816
Phe	Val	Gln	Gln	Arg	Lys	Glu	Ala	Leu	Glu	Lys	Thr	Gly	Glu	Ile	Arg	
				260				265					270			
TGC	GCC	ATG	GAC	CAC	ATC	CTG	GAA	GCC	GAA	AGG	AAG	GGC	GAG	ATC	AAC	864
Cys	Ala	Met	Asp	His	Ile	Leu	Glu	Ala	Glu	Arg	Lys	Gly	Glu	Ile	Asn	
		275					280					285				
CAC	GAC	AAC	GTC	CTC	TAC	ATC	GTC	GAG	AAC	ATC	AAC	GTC	GCA	GCC	ATC	912
His	Asp	Asn	Val	Leu	Tyr	Ile	Val	Glu	Asn	Ile	Asn	Val	Ala	Ala	Ile	
	290					295					300					
GAG	ACG	ACG	CTG	TGG	TCG	ATC	GAG	TGG	GGC	CTC	GCG	GAG	CTG	GTG	AAC	960
Glu	Thr	Thr	Leu	Trp	Ser	Ile	Glu	Trp	Gly	Leu	Ala	Glu	Leu	Val	Asn	
305					310				315						320	
CAC	CCG	GAG	ATC	CAG	CAG	AAG	CTG	CGC	GAG	GAG	ATC	GTC	GCC	GTT	CTG	1008
His	Pro	Glu	Ile	Gln	Gln	Lys	Leu	Arg	Glu	Glu	Ile	Val	Ala	Val	Leu	
				325				330						335		
GGC	GCC	GGC	GTG	GCG	GTG	ACG	GAG	CCG	GAC	CTG	GAG	CGC	CTC	CCC	TAC	1056
Gly	Ala	Gly	Val	Ala	Val	Thr	Glu	Pro	Asp	Leu	Glu	Arg	Leu	Pro	Tyr	
			340					345					350			
CTG	CAG	TCC	GTG	GTG	AAG	GAG	ACG	CTC	CGC	CTC	CGC	ATG	GCA	ATC	CCG	1104
Leu	Gln	Ser	Val	Val	Lys	Glu	Thr	Leu	Arg	Leu	Arg	Met	Ala	Ile	Pro	
		355					360					365				
CTC	CTG	GTG	CCG	CAC	ATG	AAC	CTC	AGC	GAC	GCC	AAG	CTC	GCC	GGC	TAC	1152
Leu	Leu	Val	Pro	His	Met	Asn	Leu	Ser	Asp	Ala	Lys	Leu	Ala	Gly	Tyr	
		370				375					380					
GAC	ATC	CCC	GCC	GAG	TCC	AAG	ATC	CTC	GTC	AAC	GCC	TGG	TTC	CTC	GCC	1200
Asp	Ile	Pro	Ala	Glu	Ser	Lys	Ile	Leu	Val	Asn	Ala	Trp	Phe	Leu	Ala	
385					390					395					400	
AAC	GAC	CCC	AAG	CGG	TGG	GTG	CGC	GCC	GAT	GAG	TTC	AGG	CCG	GAG	AGG	1248
Asn	Asp	Pro	Lys	Arg	Trp	Val	Arg	Ala	Asp	Glu	Phe	Arg	Pro	Glu	Arg	
				405				410						415		
TTC	CTC	GAG	GAG	GAG	AAG	GCC	GTC	GAG	GCC	CAC	GGC	AAC	GAT	TTC	CGG	1296
Phe	Leu	Glu	Glu	Glu	Lys	Ala	Val	Glu	Ala	His	Gly	Asn	Asp	Phe	Arg	
			420					425					430			
TTC	GTG	CCC	TTC	GGC	GTC	GGC	CGC	CGG	AGC	TGC	CCC	GGG	ATC	ATC	CTC	1344
Phe	Val	Pro	Phe	Gly	Val	Gly	Arg	Arg	Ser	Cys	Pro	Gly	Ile	Ile	Leu	
		435					440					445				
GCG	CTG	CCC	ATC	ATC	GGC	ATC	ACG	CTC	GGA	CGC	CTG	GTG	CAG	AAC	TTC	1392
Ala	Leu	Pro	Ile	Ile	Gly	Ile	Thr	Leu	Gly	Arg	Leu	Val	Gln	Asn	Phe	
		450				455					460					
CAG	CTG	CTG	CCG	CCG	CCG	GGG	CAG	GAC	AAG	ATC	GAC	ACC	ACC	GAG	AAG	1440
Gln	Leu	Leu	Pro	Pro	Pro	Gly	Gln	Asp	Lys	Ile	Asp	Thr	Thr	Glu	Lys	
					470				475					480		
CCC	GGG	CAG	TTT	ACC	AAC	CAG	ATC	CTC	AAG	CAC	GCC	ACC	ATT	GTC	TGC	1488
Pro	Gly	Gln	Phe	Thr	Asn	Gln	Ile	Leu	Lys	His	Ala	Thr	Ile	Val	Cys	
				485				490						495		
AAG	CCA	CTC	GAG	GCT	TAA											1506
Lys	Pro	Leu	Glu	Ala												
			500													

(2) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1506 base pairs
 - (B) TYPE: nucleotide
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1..1503
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

CDS: 1..1503

ATG GAT GTT TTG TTG TTG GAA AAA GCT TTG TTG GGT TTG TTC GCC GCG Met Asp Val Leu Leu Leu Glu Lys Ala Leu Leu Gly Leu Phe Ala Ala 1 5 10 15	48
GCG GTG CTG GCC ATC GCC GTC GCC AAG CTC ACC GGC AAG CGC TTC CGC Ala Val Leu Ala Ile Ala Val Ala Lys Leu Thr Gly Lys Arg Phe Arg 20 25 30	96
CTC CCC CCT GGC CCC TCC GGC GCC CCC ATC GTC GGC AAC TGG CTG CAG Leu Pro Pro Gly Pro Ser Gly Ala Pro Ile Val Gly Asn Trp Leu Gln 35 40 45	144
GTC GGC GAC GAC CTC AAC CAC CGC AAC CTG ATG GGC CTG GCC AAG CGG Val Gly Asp Asp Leu Asn His Arg Asn Leu Met Gly Leu Ala Lys Arg 50 55 60	192
TTC GGC GAG GTG TTC CTC CTC CGC ATG GGC GTC CGC AAC CTG GTG GTC Phe Gly Glu Val Phe Leu Leu Arg Met Gly Val Arg Asn Leu Val Val 65 70 75 80	240
GTC TCC AGC CCC GAG CTC GCC AAG GAG GTC CTC CAC ACC CAG GGC GTC Val Ser Ser Pro Glu Leu Ala Lys Glu Val Leu His Thr Gln Gly Val 85 90 95	288
GAG TTC GGC TCC CGC ACC CGC AAC GTC GTC TTC GAC ATC TTC ACC GGC Glu Phe Gly Ser Arg Thr Arg Asn Val Val Phe Asp Ile Phe Thr Gly 100 105 110	336
AAG GGA CAG GAC ATG GTG TTC ACG GTG TAC GGC GAC CAC TGG CGC AAG Lys Gly Gln Asp Met Val Phe Thr Val Tyr Gly Asp His Trp Arg Lys 115 120 125	384
ATG CGG CGG ATC ATG ACG GTG CCC TTC TTC ACC AAC AAG GTG GTG GCG Met Arg Arg Ile Met Thr Val Pro Phe Phe Thr Asn Lys Val Val Ala 130 135 140	432
CAG AAC CGC GTG GGG TGG GAG GAG GAG GCC CGG CTG GTG GTG GAG GAC Gln Asn Arg Val Gly Trp Glu Glu Glu Ala Arg Leu Val Val Glu Asp 145 150 155 160	480
CTC AAG GCC GAC CCG GCG GCG GCG ACG GCG GGC GTG GTG GTC CGC CGC Leu Lys Ala Asp Pro Ala Ala Ala Thr Ala Gly Val Val Val Arg Arg 165 170 175	528
AGG CTG CAG CTC ATG ATG TAC AAC GAC ATG TTC CGC ATC ATG TTC GAC Arg Leu Gln Leu Met Met Tyr Asn Asp Met Phe Arg Ile Met Phe Asp 180 185 190	576
CGC CGG TTC GAG AGC GTG GCC GAC CCG CTC TTC AAC CAG CTC AAG GCG Arg Arg Phe Glu Ser Val Ala Asp Pro Leu Phe Asn Gln Leu Lys Ala 195 200 205	624

00577 46267260

CCT Leu	AAC Asn 210	GCC Ala	GAG Glu	CGC Arg	AGC Ser	ATC Ile 215	CTC Leu	TCC Ser	CAG Gln	AGC Ser	TTC Phe 220	GAC Asp	TAC Tyr	AAC Asn	TAC Tyr	672
GGC Gly 225	GAC Asp	TTC Phe	ATC Ile	CCC Pro	GTC Val 230	CTC Leu	CGC Arg	CCC Pro	TTC Phe 235	CTC Leu 235	CGC Arg	CGC Arg	TAC Tyr	CTC Leu	AAC Asn 240	720
CGC Arg	TGC Cys	ACC Thr	AAC Asn	CTC Leu 245	AAG Lys	ACC Thr	AAG Lys	CGG Arg	ATG Met 250	AAG Lys	GTG Val	TTC Phe	GAG Glu	GAC Asp 255	CAC His	768
TTC Phe	GTC Val	CAG Gln 260	CAG Gln 260	CGC Arg	AAG Lys	GAG Glu	CGC Ala	TTG Leu 265	GAG Glu	AAG Lys	ACG Thr	GGT Gly	GAG Glu 270	ATC Ile	AGG Arg	816
TGC Cys	GCC Ala 275	ATG Met	GAC Asp	CAC His	ATC Ile	CTG Leu	GAA Glu 280	GCC Ala	GAA Glu	AGG Arg	AAG Lys	GGC Gly 285	GAG Glu	ATC Ile	AAC Asn	864
CAC His	GAC Asp 290	AAC Asn	GTC Val	CTC Leu	TAC Tyr	ATC Ile 295	GTC Val	GAG Glu	AAC Asn	ATC Ile 300	AAC Asn 300	GTC Val	GCA Ala	GCC Ala	ATC Ile	912
GAG Glu 305	ACG Thr	ACG Thr	CTG Leu	TGG Trp	TCG Ser 310	ATC Ile	GAG Glu	TGG Trp	GGC Gly	CTC Leu 315	GCG Ala	GAG Glu	CTG Leu	GTG Val	AAC Asn 320	960
CAC His	CCG Pro	GAG Glu	ATC Ile	CAG Gln 325	CAG Gln	AAG Lys	CTG Leu	CGC Arg	GAG Glu 330	GAG Glu	ATC Ile	GTC Val	GCC Ala	GTT Val 335	CTG Leu	1008
GGC Gly	GCC Gly	GGC Gly	GTG Val 340	GCG Ala	GTG Val	ACG Thr	GAG Glu	CCG Pro 345	GAC Asp	CTG Leu	GAG Glu	CGC Arg	CTC Leu 350	CCC Pro	TAC Tyr	1056
CTG Leu	CAG Gln 355	TCC Ser	GTG Val	GTG Val	AAG Lys	GAG Glu 360	ACG Thr	CTC Leu	CGC Arg	CTC Leu	CGC Arg	ATG Met 365	GCA Ala	ATC Ile	CCG Pro	1104
CTC Leu	CTG Leu 370	GTG Val	CCG Pro	CAC His	ATG Met	AAC Asn 375	CTC Leu	AGC Ser	GAC Asp	GCC Ala	AAG Lys 380	CTC Leu	GCC Ala	GGC Gly	TAC Tyr	1152
GAC Asp 385	ATC Ile	CCC Pro	GCC Ala	GAG Glu	TCC Ser 390	AAG Lys	ATC Ile	CTC Leu	GTC Val	AAC Asn 395	GCC Ala	TGG Trp	TTC Phe	CTC Leu	GCC Ala 400	1200
AAC Asn	GAC Asp	CCC Pro	AAG Lys	CGG Arg 405	TGG Trp	GTG Val	CGC Arg	GCC Ala	GAT Asp 410	GAG Glu	TTC Phe	AGG Arg	CCG Pro	GAG Glu 415	AGG Arg	1248
TTC Phe	CTC Leu	GAG Glu	GAG Glu 420	GAG Glu	AAG Lys	GCC Ala	GTC Val	GAG Glu 425	GCC Ala	CAC His	GGC Gly	AAC Asn	GAT Asp 430	TTC Phe	CGG Arg	1296
TTC Phe	GTG Val	CCC Pro 435	TTC Phe	GGC Gly	GTC Val	GGC Gly 440	CGC Arg	CGG Arg	AGC Ser	TGC Cys	CCC Pro	GGG Gly 445	ATC Ile	ATC Ile	CTC Leu	1344
GCG Ala 450	CTG Leu	CCC Pro	ATC Ile	ATC Ile	GGC Gly 455	ATC Ile	ACG Thr	CTC Leu	GGA Gly	CGC Arg	CTG Leu 460	GTG Val	CAG Gln	AAC Asn	TTC Phe	1392
CAG Gln 465	CTG Leu	CTG Leu	CCG Pro	CCG Pro	CCG Pro 470	GGG Gly	CAG Gln	GAC Asp	AAG Lys	ATC Ile 475	GAC Asp	ACC Thr	ACC Thr	GAG Glu	AAG Lys 480	1440

[illegible]

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1506 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1503

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

ATG Met	GAT Asp	GTT Val	TTG Leu 505	TTG Leu	TTG Leu	GAA Glu	AAA Lys	GCT Ala 510	TTG Leu	TTG Leu	GGT Gly	TTG Leu	TTT Phe 515	GCT Ala	GCT Ala	48
GCT Ala	GTT Val	TTG Leu 520	GCT Ala	ATT Ile	GCT Ala	GTT Val	GCT Ala 525	AAA Lys	TTG Leu	ACT Thr	GGT Gly	AAA Lys 530	AGA Arg	TTT Phe	AGA Arg	96
TTG Leu	CCA Pro	CCA Pro 35	GGT Gly	CCA Pro	TCC Ser	GGC Gly	GCC Ala 40	CCC Pro	ATC Ile	GTC Val	GGC Gly	AAC Asn 45	TGG Trp	CTG Leu	CAG Gln	144
GTC Val	GGC Gly 50	GAC Asp	GAC Asp	CTC Leu	AAC Asn	CAC His 55	CGC Arg	AAC Asn	CTG Leu	ATG Met	GGC Gly 60	CTG Leu	GCC Ala	AAG Lys	CGG Arg	192
TTC Phe 65	GGC Gly	GAG Glu	GTG Val	TTC Phe	CTC Leu 70	CTC Leu	CGC Arg	ATG Met	GGC Gly	GTC Val 75	CGC Arg	AAC Asn	CTG Leu	GTG Val	GTC Val 80	240
GTC Val	TCC Ser	AGC Ser	CCC Pro	GAG Glu 85	CTC Leu	GCC Ala	AAG Lys	GAG Glu 90	GTC Val	CTC Leu	CAC His	ACC Thr	CAG Gln	GGC Gly 95	GTC Val	288
GAG Glu	TTC Phe	GGC Gly	TCC Ser 100	CGC Arg	ACC Thr	CGC Arg	AAC Asn	GTC Val 105	GTC Val	TTC Phe	GAC Asp	ATC Ile	TTC Phe 110	ACC Thr	GGC Gly	336
AAG Lys	GGA Gly	CAG Gln 115	GAC Asp	ATG Met	GTG Val	TTC Phe	ACG Thr 120	GTG Val	TAC Tyr	GGC Gly	GAC Asp	CAC His 125	TGG Trp	CGC Arg	AAG Lys	384
ATG Met	CGG Arg 130	CGG Arg	ATC Ile	ATG Met	ACG Thr	GTG Val 135	CCC Pro	TTC Phe	TTC Phe	ACC Thr	AAC Asn 140	AAG Lys	GTG Val	GTG Val	GCG Ala	432
CAG Gln 145	AAC Asn	CGC Arg	GTG Val	GGG Gly	TGG Trp 150	GAG Glu	GAG Glu	GAG Glu	GCC Ala	CGG Arg 155	CTG Leu	GTG Val	GTG Val	GAG Glu 160	GAC Asp	480
CTC Leu	AAG Lys	GCC Ala	GAC Asp	CCG Pro 165	GCG Ala	GCG Ala	GCG Ala	ACG Thr	GCG Ala 170	GGC Gly	GTG Val	GTG Val	GTC Val	CGC Arg 175	CGC Arg	528

AGG	CTG	CAG	CTC	ATG	ATG	TAC	AAC	GAC	ATG	TTC	CGC	ATC	ATG	TTC	GAC	576
Arg	Leu	Gln	Leu	Met	Met	Tyr	Asn	Asp	Met	Phe	Arg	Ile	Met	Phe	Asp	
			180					185					190			
CGC	CGG	TTC	GAG	AGC	GTG	GCC	GAC	CCG	CTC	TTC	AAC	CAG	CTC	AAG	GCG	624
Arg	Arg	Phe	Glu	Ser	Val	Ala	Asp	Pro	Leu	Phe	Asn	Gln	Leu	Lys	Ala	
		195					200					205				
CTC	AAC	GCC	GAG	CGC	AGC	ATC	CTC	TCC	CAG	AGC	TTC	GAC	TAC	AAC	TAC	672
Leu	Asn	Ala	Glu	Arg	Ser	Ile	Leu	Ser	Gln	Ser	Phe	Asp	Tyr	Asn	Tyr	
	210					215					220					
GGC	GAC	TTC	ATC	CCC	GTG	CTC	CGC	CCC	TTC	CTC	CGC	CGC	TAC	CTC	AAC	720
Gly	Asp	Phe	Ile	Pro	Val	Leu	Arg	Pro	Phe	Leu	Arg	Arg	Tyr	Leu	Asn	
	225				230				235					240		
CGC	TGC	ACC	AAC	CTC	AAG	ACC	AAG	CGG	ATG	AAG	GTG	TTC	GAG	GAC	CAC	768
Arg	Cys	Thr	Asn	Leu	Lys	Thr	Lys	Arg	Met	Lys	Val	Phe	Glu	Asp	His	
			245					250					255			
TTC	GTC	CAG	CAG	CGC	AAG	GAG	GCG	TTG	GAG	AAG	ACG	GGT	GAG	ATC	AGG	816
Phe	Val	Gln	Gln	Arg	Lys	Glu	Ala	Leu	Glu	Lys	Thr	Gly	Glu	Ile	Arg	
		260					265						270			
TGC	GCC	ATG	GAC	CAC	ATC	CTG	GAA	GCC	GAA	AGG	AAG	GGC	GAG	ATC	AAC	864
Cys	Ala	Met	Asp	His	Ile	Leu	Glu	Ala	Glu	Arg	Lys	Gly	Glu	Ile	Asn	
		275					280					285				
CAC	GAC	AAC	GTC	CTC	TAC	ATC	GTC	GAG	AAC	ATC	AAC	GTC	GCA	GCC	ATC	912
His	Asp	Asn	Val	Leu	Tyr	Ile	Val	Glu	Asn	Ile	Asn	Val	Ala	Ala	Ile	
	290					295					300					
GAG	ACG	ACG	CTG	TGG	TCG	ATC	GAG	TGG	GGC	CTC	GCG	GAG	CTG	GTG	AAC	960
Glu	Thr	Thr	Leu	Trp	Ser	Ile	Glu	Trp	Gly	Leu	Ala	Glu	Leu	Val	Asn	
	305			310					315					320		
CAC	CCG	GAG	ATC	CAG	CAG	AAG	CTG	CGC	GAG	GAG	ATC	GTC	GCC	GTT	CTG	1008
His	Pro	Glu	Ile	Gln	Gln	Lys	Leu	Arg	Glu	Glu	Ile	Val	Ala	Val	Leu	
			325					330					335			
GGC	GCC	GGC	GTG	GCG	GTG	ACG	GAG	CCG	GAC	CTG	GAG	CGC	CTC	CCC	TAC	1056
Gly	Ala	Gly	Val	Ala	Val	Thr	Glu	Pro	Asp	Leu	Glu	Arg	Leu	Pro	Tyr	
		340					345					350				
CTG	CAG	TCC	GTG	GTG	AAG	GAG	ACG	CTC	CGC	CTC	CGC	ATG	GCA	ATC	CCG	1104
Leu	Gln	Ser	Val	Val	Lys	Glu	Thr	Leu	Arg	Leu	Arg	Met	Ala	Ile	Pro	
		355					360					365				
CTC	CTG	GTG	CCG	CAC	ATG	AAC	CTC	AGC	GAC	GCC	AAG	CTC	GCC	GGC	TAC	1152
Leu	Leu	Val	Pro	His	Met	Asn	Leu	Ser	Asp	Ala	Lys	Leu	Ala	Gly	Tyr	
	370					375					380					
GAC	ATC	CCC	GCC	GAG	TCC	AAG	ATC	CTC	GTC	AAC	GCC	TGG	TTC	CTC	GCC	1200
Asp	Ile	Pro	Ala	Glu	Ser	Lys	Ile	Leu	Val	Asn	Ala	Trp	Phe	Leu	Ala	
	385				390				395					400		
AAC	GAC	CCC	AAG	CGG	TGG	GTG	CGC	GCC	GAT	GAG	TTC	AGG	CCG	GAG	AGG	1248
Asn	Asp	Pro	Lys	Arg	Trp	Val	Arg	Ala	Asp	Glu	Phe	Arg	Pro	Glu	Arg	
			405				410						415			
TTC	CTC	GAG	GAG	GAG	AAG	GCC	GTC	GAG	GCC	CAC	GGC	AAC	GAT	TTC	CGG	1296
Phe	Leu	Glu	Glu	Glu	Lys	Ala	Val	Glu	Ala	His	Gly	Asn	Asp	Phe	Arg	
		420					425					430				
TTC	GTG	CCC	TTC	GGC	GTC	GGC	CGC	CGG	AGC	TGC	CCC	GGG	ATC	ATC	CTC	1344
Phe	Val	Pro	Phe	Gly	Val	Gly	Arg	Arg	Ser	Cys	Pro	Gly	Ile	Ile	Leu	
		435					440					445				

00577 462260

[illegible]

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2181 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 112..1734

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

[illegible]

CTC Leu 115	GGC Gly	GAC Asp	GGC Gly	ATC Ile	TTC Phe 120	AAT Asn	TCC Ser	GAC Asp	GGC Gly	GAC Asp 125	ACC Thr	TGG Trp	CTC Leu	GCG Ala	CAG Gln 130	501
CGC Arg	AAG Lys	ACG Thr	GCC Ala 135	CGC Ala 135	CTC Leu	GAG Glu	TTC Phe	ACC Thr 140	ACC Thr 140	CGC Arg	ACG Thr	CTC Leu	CGG Arg	ACG Thr 145	GCC Ala	549
ATG Met	TCC Ser	CGC Arg	TGG Trp 150	GTC Val	TCG Ser	CGC Arg	TCC Ser	ATC Ile 155	CAC His	GGC Gly	CGC Arg	CTC Leu	CTG Leu 160	CCC Pro	ATC Ile	597
CTG Leu	GCC Ala 165	GAC Asp	GGC Ala	GCC Ala	AAG Lys	GGC Gly	AAG Lys 170	CGC Ala	CAG Gln	GTG Val	GAT Asp 175	CTC Leu 175	CAG Gln	GAC Asp	CTC Leu	645
CTC Leu 180	CTC Leu	CGC Arg	CTC Leu	ACC Thr	TTC Phe 185	GAC Asp 185	AAC Asn	ATC Ile	TGC Cys	GGC Gly 190	CTG Leu 190	GCC Ala	TTC Phe	GGC Gly	AAG Lys	693
GAC Asp 195	CCG Pro	GAG Glu	ACG Thr	CTC Leu 200	GCC Gln 200	CAG Gln	GGC Gly	CTG Leu 205	CCG Pro 205	GAG Glu 205	AAC Asn	GAG Glu	TTC Phe	GCC Ala 210	TCC Ser 210	741
GCG Ala	TTC Phe	GAC Asp	CGC Arg	GCC Ala 215	ACC Thr	GAG Glu	GCC Ala	ACG Thr 220	CTC Leu 220	AAC Asn	CGC Arg	TTC Phe	ATC Ile 225	TTC Phe 225	CCG Pro	789
GAG Glu	TTC Phe	CTG Leu	TGG Trp 230	CGC Arg	TGC Cys	AAA Lys	AAG Lys 235	TGG Trp 235	CTG Leu	GGC Gly	CTC Leu	GGC Gly	ATG Met 240	GAG Glu 240	ACC Thr	837
ACG Thr	CTG Leu 245	ACC Ser	AGC Ser	AGC Met	ATG Met	GCC Ala	CAC His 250	GTC Val	GAC Asp	CAG Gln	TAC Tyr	CTC Leu 255	GCC Ala	GCC Ala	GTC Val	885
ATC Ile 260	AAG Lys	AAG Lys	CGC Arg	AAG Lys	CTC Leu 265	GAG Glu 265	CTC Leu	GCC Ala	GCC Ala	GGC Gly 270	AAC Asn	GGC Gly	AAA Lys	TGC Cys	GAC Asp	933
ACG Thr 275	GCG Ala	GCG Ala	ACG Thr	CAC His	GAC Asp 280	GAC Asp	CTG Leu	CTC Leu	TCC Ser	CGG Arg 285	TTC Phe	ATG Met	CGG Arg	AAG Lys	GGT Gly 290	981
TCC Ser	TAC Tyr	TCG Ser	GAC Asp 295	GAG Glu	TCG Ser	CTC Leu	CAG Gln	CAC His	GTG Val 300	GCG Ala	CTC Leu	AAC Asn	TTC Phe	ATC Ile 305	CTC Leu	1029
GCC Ala	GGC Gly	CGC Arg	GAC Asp 310	ACC Thr	TCC Ser	TCC Ser	GTG Val 315	GCG Ala 315	CTC Leu	TCC Ser	TGG Trp	TTC Phe	TTC Phe 320	TGG Trp	CTC Leu	1077
GTG Val	TCC Ser 325	ACC Thr	CAC His	CCT Pro	GCG Ala	GTG Val	GAG Glu 330	CGC Arg	AAG Lys	ATC Ile	GTG Val 335	CGC Arg	GAG Glu	CTC Leu	TGC Cys	1125
TCC Ser 340	GTG Val	CTC Leu	GCC Ala	GCG Ala	TCA Ser 345	CGG Arg 345	GGC Gly	GCC Ala	CAT His	GAC Asp 350	CCG Pro	GCA Ala	TTG Leu	TGG Trp	CTG Leu	1173
GCG Ala 355	GAG Glu	CCC Pro	TTC Phe	ACC Thr	TTC Glu 360	GAG Glu	GAG Glu	CTC Leu	GAC Asp	CGC Arg 365	CTG Leu	GTC Val	TAC Tyr	CTC Leu 370	AAG Lys	1221
GCG Ala	GCG Ala	CTG Leu	TCG Ser	GAG Glu 375	ACC Thr	CTC Leu	CGC Arg	CTC Leu	TAC Tyr 380	CCC Pro	TCC Ser	GTC Val	CCC Pro	GAG Glu 385	GAC Asp	1269

0971394 1100

TCC AAG CAC GTC GTC GCG GAC GAC TAC CTC CCC GAC GGC ACC TTC GTG 1317
 Ser Lys His Val Val Ala Asp Asp Tyr Leu Pro Asp Gly Thr Phe Val
 390 395 400
 CCG GCC GGG TCG TCG GTC ACC TAC TCC ATA TAC TCG GCG GGG CGC ATG 1365
 Pro Ala Gly Ser Ser Val Thr Tyr Ser Ile Tyr Ser Ala Gly Arg Met
 405 410 415
 AAG GGG GTG TGG GGG GAG GAC TGC CTC GAG TTC CGG CCG GAG CGA TGG 1413
 Lys Gly Val Trp Gly Glu Asp Cys Leu Glu Phe Arg Pro Glu Arg Trp
 420 425 430
 CTG TCG GCC GAC GGC ACC AAG TTC GAG CAG CAC GAC TCG TAC AAG TTC 1461
 Leu Ser Ala Asp Gly Thr Lys Phe Glu Gln His Asp Ser Tyr Lys Phe
 435 440 445 450
 GTG GCG TTC AAC GCC GGG CCG AGG GTG TGC CTG GGC AAG GAC CTA GCC 1509
 Val Ala Phe Asn Ala Gly Pro Arg Val Cys Leu Gly Lys Asp Leu Ala
 455 460 465
 TAC CTG CAG ATG AAG AAC ATC GCC GGG AGC GTG CTG CTC CGG CAC CGC 1557
 Tyr Leu Gln Met Lys Asn Ile Ala Gly Ser Val Leu Leu Arg His Arg
 470 475 480
 CTG ACC GTG GCG CCG GGC CAC CGC GTG GAG CAG AAG ATG TCG CTC ACG 1605
 Leu Thr Val Ala Pro Gly His Arg Val Glu Gln Lys Met Ser Leu Thr
 485 490 495
 CTC TTC ATG AAG GGC GGG CTA CGG ATG GAG GTA CGT CCG CGC GAC CTC 1653
 Leu Phe Met Lys Gly Gly Leu Arg Met Glu Val Arg Pro Arg Asp Leu
 500 505 510
 GCC CCC GTC CTC GAC GAG CCC TGC GGC CTG GAC GCC GGC GCC GCC ACC 1701
 Ala Pro Val Leu Asp Glu Pro Cys Gly Leu Asp Ala Gly Ala Ala Thr
 515 520 525 530
 GCC GCC GCA GCA AGT GCC ACA GCG CCG TGC GCG TAGAAGACCT GGCACCGGCA 1754
 Ala Ala Ala Ala Ser Ala Thr Ala Pro Cys Ala
 535 540
 CGCGCCATGC ATGATTCGTG CGTGCTAGCT GTTGAAGGGA CGCCGGACAT TGAATGTGTA 1814
 GATAGGGCAG CAGTGCAAGA CCGTAAGTAA AATTGATGAT GGGTTTGGTG ACAACATTGA 1874
 AGCCACTCCT TTCCAGAATT TACGACCCGG ATAGGAGAAA CAGGGAAACT TTGCAGATCA 1934
 CAACACAAGA TCTAGCCAGC CGGGGATCTG ATCTGATTTG CGTCTGCTCG GAGCACGGGT 1994
 GCATGGGAGA CCAAGGAGGA AAACAAAAA TAACAGAAAC AGAGTGAGCA ATATTTGTGA 2054
 TTGTAGCCAC GGGAAAGAGA GAGGAGTAAT TAGTAATTCA GATTTGTTTG CAGTAGCTCG 2114
 GTGTTGGTGA CCAGATCATA GCCAACTAGG CTATTCTATT CTATTCTATT TTTGAAGATG 2174
 ATTTTTC 2181

00577 46257260

(2) INFORMATION FOR SEQ ID NO: 11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 150 base pairs
 - (B) TYPE: nucleotide
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "primer"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

ATATATGGAT CCATGGAGGT GGGGACGTGG GCGGTGGTG

39

(2) INFORMATION FOR SEQ ID NO: 12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 150 base pairs
 - (B) TYPE: nucleotide
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "primer"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

ATATATGGAT CCATGGAAGT TGGTACTTGG GCTGTTGTTG TTTCTGCTGT TGCTGCTTAT 60
 ATGGCTTGGT TTTGGAGAAT GTCTAGAGGT TTGAGAGGTC CAAGAGTTTG GCCAGTTTGT 120
 GGTTCCTTGC CAGGCCTGCT GCAGCACGCC 150

(2) INFORMATION FOR SEQ ID NO: 13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 42 base pairs
 - (B) TYPE: nucleotide

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "reverse"
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

TATATAGAAT TCCTTCTACG CGCACGGCGC TGTGGCACTT GC

42

(2) INFORMATION FOR SEQ ID NO: 14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1626 base pairs
 - (B) TYPE: nucleotide
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1..1623
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

ATG GAA GTT GGT ACT TGG GCT GTT GTT GTT TCT GCT GTT GCT GCT TAT	48
Met Glu Val Gly Thr Trp Ala Val Val Val Ser Ala Val Ala Ala Tyr	
1 5 10 15	
ATG GCT TGG TTT TGG AGA ATG TCT AGA GGT TTG AGA GGT CCA AGA GTT	96
Met Ala Trp Phe Trp Arg Met Ser Arg Gly Leu Arg Gly Pro Arg Val	
20 25 30	
TGG CCA GTT TTG GGT TCT TTG CCA GCC CTG GTG CAG CAC GCC GAG GAC	144
Trp Pro Val Leu Gly Ser Leu Pro Gly Leu Val Gln His Ala Glu Asp	
35 40 45	

00577 4626260

ATG CAC GAG TGG ATC GCC GGC AAC CTG CGC CGC GCG GGC GGC ACG TAC	192
Met His Glu Trp Ile Ala Gly Asn Leu Arg Arg Ala Gly Gly Thr Tyr	
50 55 60	
CAG ACC TGC ATC TTC GCC GTG CCC GGG GTG GCG CGC CGC GGC GGC CTG	240
Gln Thr Cys Ile Phe Ala Val Pro Gly Val Ala Arg Arg Gly Gly Leu	
65 70 75 80	
GTC ACC GTC ACC TGC GAC CCG CGC AAC CTG GAG CAC GTC CTG AAG GCG	288
Val Thr Val Thr Cys Asp Pro Arg Asn Leu Glu His Val Leu Lys Ala	
85 90 95	
CGC TTC GAC AAC TAC CCC AAG GGC CCC TTC TGG CAC GGC GTC TTC CGG	336
Arg Phe Asp Asn Tyr Pro Lys Gly Pro Phe Trp His Gly Val Phe Arg	
100 105 110	
GAC CTG CTC GGC GAC GGC ATC TTC AAT TCC GAC GGC GAC ACC TGG CTC	384
Asp Leu Leu Gly Asp Gly Ile Phe Asn Ser Asp Gly Asp Thr Trp Leu	
115 120 125	
GCG CAG CGC AAG ACG GCC GCG CTC GAG TTC ACC ACC CGC ACG CTC CGG	432
Ala Gln Arg Lys Thr Ala Ala Leu Glu Phe Thr Thr Arg Thr Leu Arg	
130 135 140	
ACG GCC ATG TCC CGC TGG GTC TCG CGC TCC ATC CAC GGC CGC CTC CTG	480
Thr Ala Met Ser Arg Trp Val Ser Arg Ser Ile His Gly Arg Leu Leu	
145 150 155 160	
CCC ATC CTG GCC GAC GCG GCC AAG GGC AAG GCG CAG GTG GAT CTC CAG	528
Pro Ile Leu Ala Asp Ala Ala Lys Gly Lys Ala Gln Val Asp Leu Gln	
165 170 175	
GAC CTC CTC CTC CGC CTC ACC TTC GAC AAC ATC TGC GGC CTG GCC TTC	576
Asp Leu Leu Leu Arg Leu Thr Phe Asp Asn Ile Cys Gly Leu Ala Phe	
180 185 190	
GGC AAG GAC CCG GAG ACG CTC GCC CAG GGC CTG CCG GAG AAC GAG TTC	624
Gly Lys Asp Pro Glu Thr Leu Ala Gln Gly Leu Pro Glu Asn Glu Phe	
195 200 205	
GCC TCC GCG TTC GAC CGC GCC ACC GAG GCC ACG CTC AAC CGC TTC ATC	672
Ala Ser Ala Phe Asp Arg Ala Thr Glu Ala Thr Leu Asn Arg Phe Ile	
210 215 220	
TTC CCG GAG TTC CTG TGG CGC TGC AAA AAG TGG CTG GGC CTC GGC ATG	720
Phe Pro Glu Phe Leu Trp Arg Cys Lys Lys Trp Leu Gly Leu Gly Met	
225 230 235 240	
GAG ACC ACG CTG ACC AGC AGC ATG GCC CAC GTC GAC CAG TAC CTC GCC	768
Glu Thr Thr Leu Thr Ser Ser Met Ala His Val Asp Gln Tyr Leu Ala	
245 250 255	
GCC GTC ATC AAG AAG CGC AAG CTC GAG CTC GCC GCC GGC AAC GGC AAA	816
Ala Val Ile Lys Lys Arg Lys Leu Glu Leu Ala Ala Gly Asn Gly Lys	
260 265 270	
TGC GAC ACG GCG GCG ACG CAC GAC GAC CTG CTC TCC CGG TTC ATG CGG	864
Cys Asp Thr Ala Ala Thr His Asp Asp Leu Leu Ser Arg Phe Met Arg	
275 280 285	
AAG GGT TCC TAC TCG GAC GAG TCG CTC CAG CAC GTG GCG CTC AAC TTC	912
Lys Gly Ser Tyr Ser Asp Glu Ser Leu Gln His Val Ala Leu Asn Phe	
290 295 300	
ATC CTC GCC GGC CGC GAC ACC TCC TCC GTG GCG CTC TCC TGG TTC TTC	960
Ile Leu Ala Gly Arg Asp Thr Ser Ser Val Ala Leu Ser Trp Phe Phe	
305 310 315 320	

00577 452260

TGG	CTC	GTG	TCC	ACC	CAC	CCT	GCG	GTG	GAG	CGC	AAG	ATC	GTG	CGC	GAG	1008
Trp	Leu	Val	Ser	Thr	His	Pro	Ala	Val	Glu	Arg	Lys	Ile	Val	Arg	Glu	
				325					330					335		
CTC	TGC	TCC	GTT	CTC	GCC	GCG	TCA	CGG	GGC	GCC	CAT	GAC	CCG	GCA	TTG	1056
Leu	Cys	Ser	Val	Leu	Ala	Ala	Ser	Arg	Gly	Ala	His	Asp	Pro	Ala	Leu	
			340					345					350			
TGG	CTG	GCG	GAG	CCC	TTC	ACC	TTC	GAG	GAG	CTC	GAC	CGC	CTG	GTC	TAC	1104
Trp	Leu	Ala	Glu	Pro	Phe	Thr	Phe	Glu	Glu	Leu	Asp	Arg	Leu	Val	Tyr	
		355					360					365				
CTC	AAG	GCG	GCG	CTG	TGG	GAG	ACC	CTC	CGC	CTC	TAC	CCC	TCC	GTC	CCC	1152
Leu	Lys	Ala	Ala	Leu	Ser	Glu	Thr	Leu	Arg	Leu	Tyr	Pro	Ser	Val	Pro	
	370					375					380					
GAG	GAC	TCC	AAG	CAC	GTC	GTC	GCG	GAC	GAC	TAC	CTC	CCC	GAC	GGC	ACC	1200
Glu	Asp	Ser	Lys	His	Val	Val	Ala	Asp	Asp	Tyr	Leu	Pro	Asp	Gly	Thr	
	385				390					395				400		
TTC	GTG	CCG	GCC	GGG	TGG	TGG	GTC	ACC	TAC	TCC	ATA	TAC	TGG	GCG	GGG	1248
Phe	Val	Pro	Ala	Gly	Ser	Ser	Val	Thr	Tyr	Ser	Ile	Tyr	Ser	Ala	Gly	
			405						410					415		
CGC	ATG	AAG	GGG	GTG	TGG	GGG	GAG	GAC	TGC	CTC	GAG	TTC	CGG	CCG	GAG	1296
Arg	Met	Lys	Gly	Val	Trp	Gly	Glu	Asp	Cys	Leu	Glu	Phe	Arg	Pro	Glu	
			420				425						430			
CGA	TGG	CTG	TGG	GCC	GAC	GGC	ACC	AAG	TTC	GAG	CAG	CAC	GAC	TGG	TAC	1344
Arg	Trp	Leu	Ser	Ala	Asp	Gly	Thr	Lys	Phe	Glu	Gln	His	Asp	Ser	Tyr	
		435				440						445				
AAG	TTC	GTG	GCG	TTC	AAC	GCC	GGG	CCG	AGG	GTG	TGC	CTG	GGC	AAG	GAC	1392
Lys	Phe	Val	Ala	Phe	Asn	Ala	Gly	Pro	Arg	Val	Cys	Leu	Gly	Lys	Asp	
	450					455					460					
CTA	GCC	TAC	CTG	CAG	ATG	AAG	AAC	ATC	GCC	GGG	AGC	GTG	CTG	CTC	CGG	1440
Leu	Ala	Tyr	Leu	Gln	Met	Lys	Asn	Ile	Ala	Gly	Ser	Val	Leu	Leu	Arg	
	465				470					475				480		
CAC	CGC	CTG	ACC	GTG	GCG	CCG	GGC	CAC	CGC	GTG	GAG	CAG	AAG	ATG	TGG	1488
His	Arg	Leu	Thr	Val	Ala	Pro	Gly	His	Arg	Val	Glu	Gln	Lys	Met	Ser	
			485						490					495		
CTC	ACG	CTC	TTC	ATG	AAG	GCG	GGG	CTA	CGG	ATG	GAG	GTA	CGT	CCG	CGC	1536
Leu	Thr	Leu	Phe	Met	Lys	Gly	Gly	Leu	Arg	Met	Glu	Val	Arg	Pro	Arg	
			500					505					510			
GAC	CTC	GCC	CCC	GTC	CTC	GAC	GAG	CCC	TGC	GGC	CTG	GAC	GCC	GGC	GCC	1584
Asp	Leu	Ala	Pro	Val	Leu	Asp	Glu	Pro	Cys	Gly	Leu	Asp	Ala	Gly	Ala	
		515					520					525				
GCC	ACC	GCC	GCC	GCA	GCA	AGT	GCC	ACA	GCG	CCG	TGC	GCG	TAG			1626
Ala	Thr	Ala	Ala	Ala	Ala	Ser	Ala	Thr	Ala	Pro	Cys	Ala				
		530				535					540					

00577 4646260

CLAIMS

1. DNA sequence which encodes a protein of interest which contains regions having a high content of codons which are poorly suited to yeasts, characterized in that a sufficient number of codons which are poorly suited to yeasts is replaced with corresponding codons which are well-suited to yeasts in the said regions having a high content of codons which are poorly suited to yeasts.
2. Sequence according to claim 1, characterized in that the codons which are poorly suited to yeasts are selected from among codons whose frequency of use by yeasts is less than or equal to approximately 13 per 1000, preferably less than or equal to approximately 12 per 1000, more preferably less than or equal to approximately 10 per 1000.
3. Sequence according to claim 2, characterized in that the codons which are poorly suited to yeasts are selected from among codons CTC, CTG and CTT, which encode leucine, codons CGG, CGC, CGA, CGT and AGG, which encode arginine, codons GCG and GCC, which encode alanine, codons GGG, GGC and GGA, which encode glycine, and codons CCG and CCC, which encode proline.
4. Sequence according to claim 3, characterized in that the codons which are poorly suited to yeasts are selected from among codons CTC and CTG, which encode leucine, codons CGG, CGC, CGA, CGT

and AGG, which encode arginine, codons GCG and GCC, which encode alanine, codons GGG and GGC, which encode glycine, and codons CCG and CCC, which encode proline.

5 5. Sequence according to one of claims 1 to
4, characterized in that the corresponding codons which
are well-suited to yeasts are selected from among
codons which correspond to the codons which are poorly
suited to yeasts and which encode the same amino acids,
and whose frequency of use by yeasts is greater than 15
10 per 1000, preferably greater than or equal to 18 per
1000, more preferably greater than or equal to 20 per
1000.

6. Sequence according to claim 5,
characterized in that the corresponding codons which
15 are well-suited to yeasts are selected from among
codons TTG and TTA, preferably TTG, which encode
leucine, codon AGA, which encodes arginine, codons GCT
and GCA, preferably GCT, which encode alanine, codon
GGT, which encodes glycine, and codon CCA, which
20 encodes proline.

7. Sequence according to one of claims 1 to
7, characterized in that the regions having a high
content of codons which are poorly suited to yeasts
contain at least 2 poorly suited codons among 10
25 consecutive codons, with it being possible for the two
codons to be adjacent or separated by up to 8 other
codons.

8. Sequence according to claim 7,

0051394-1100

characterized in that the regions having a high content of poorly suited codons contain 2, 3, 4, 5 or 6 poorly suited codons per 10 consecutive codons, or contain at least 2 or 3 adjacent poorly suited codons.

5 9. DNA, in particular cDNA, sequence which encodes a protein of interest which contains regions having a high content of leucine, characterized in that a sufficient number of CTC codons encoding leucine in the said region having a high content of leucine is
10 replaced with TTG and/or TTA codons, or in that a sufficient number of CTC and CTG codons encoding leucine in the said region having a high content of leucine is replaced with TTG and/or TTA codons.

10. Sequence according to claim 9,
15 characterized in that the CTC or CTC and CTG codons are replaced with a TTG codon.

11. Sequence according to one of claims 9 or 10, characterized in that the regions having a high content of leucine contain 2, 3, 4, 5 or 6 leucines per
20 10 consecutive amino acids, or contain at least 2 or 3 adjacent leucines.

12. Sequence according to one of claims 1 to 11, characterized in that the general content of poorly suited codons is at least 20%, more preferably at least
25 30%, as compared with the total number of codons.

13. Sequence according to one of claims 1 to 12, characterized in that it contains at least one 5' region having a high content of codons which are poorly

00577 144500

suited to yeasts.

14. Sequence according to claim 13, characterized in that the codons which are poorly suited to yeasts are replaced only in this 5' region.

5 15. Sequence according to one of claims 1 to 14, characterized in that it is an isolated DNA sequence of natural origin, in particular of plant origin.

10 16. Sequence according to claim 15, characterized in that it originates from dicotyledonous or monocotyledonous plants, in particular from monocotyledonous plants.

15 17. Sequence according to claim 16, characterized in that it originates from plants of the gramineae family, which are selected, in particular, from among wheat, barley, oats, rice, maize, sorghum and cane sugar.

18. Sequence according to one of claims 1 to 17, characterized in that it encodes an enzyme.

20 19. Sequence according to claim 18, characterized in that it encodes a cytochrome P450.

25 20. Sequence according to claim 19, characterized in that the sequence which contains regions having a high content of codons which are poorly suited to yeasts includes the coding region of the sequences ID No. 1 or ID No. 10.

21. Sequence according to claim 19, characterized in that it is one of the sequences ID

00577-462460

No. 7, ID No. 8, ID No. 9 and ID No. 13.

22. Chimeric gene which contains a modified DNA sequence according to one of claims 1 to 21 and heterologous 5' and 3' regulatory elements which are
5 able to function in a yeast.

23. Vector for transforming yeasts which contains at least one chimeric gene according to claim 22.

24. Process for transforming yeasts using a
10 vector according to claim 23.

25. Transformed yeast for expressing a protein of interest, characterized in that it contains a chimeric gene according to claim 22.

26. Yeast according to claim 25,
15 characterized in that it is selected from among the genera *Saccharomyces*, *Kluyveromyces*, *Hansenula*, *Pichia* and *Yarrowia*, advantageously from the genus *Saccharomyces*, in particular *S. cerevisiae*.

27. Process for producing a heterologous
20 protein of interest in a transformed yeast, characterized in that it comprises the steps of:

a) transforming a yeast with a vector according to claim 23 which contains a modified DNA sequence according to one of claims 1 to 21 and
25 heterologous 5' and 3' regulatory elements which are able to function in a yeast,

b) culturing the transformed yeast, and

c) extracting the protein of interest from

the yeast culture.

28. Process for transforming a substrate by enzymic catalysis using an enzyme which is expressed in a yeast, which process comprises the steps of

5 a) culturing, in the presence of the
substrate to be transformed, the yeast which has been
transformed with a vector according to claim 23 which
contains a modified DNA sequence according to one of
claims 1 to 21 and heterologous 5' and 3' regulatory
10 elements which are able to function in a yeast, and
then

b) recovering the transformed substrate from the yeast culture.

THE RECODING OF DNA SEQUENCES TO ENABLE THEM TO BE
EXPRESSED IN YEASTS, AND THE TRANSFORMED YEASTS
OBTAINED

Abstract

The present invention relates to a DNA sequence which encodes a protein of interest which contains regions having a high content of codons which are poorly suited to yeasts, characterized in that a sufficient number of codons which are poorly suited to yeasts is replaced with corresponding codons which are well-suited to yeasts in the said regions having a high content of codons which are poorly suited to yeasts.

The present invention relates, more specifically, to DNA sequences which originate from dicotyledonous or monocotyledonous plants, in particular plants of the gramineae family which are selected, in particular, from among wheat, barley, oats, rice, maize, sorghum and cane sugar.

The present invention also relates to transformed yeasts which contain a DNA sequence according to the invention.

005777 46267260

COMBINED DECLARATION AND POWER OF ATTORNEY

(Original, Design, National Stage of PCT, Divisional, Continuation or C-I-P Application)

As a below named inventor, I hereby declare that: WE, YANNICK BATARD, ET AL.

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

RECODING OF DNA SEQUENCES PERMITTING EXPRESSION IN YEAST AND OBTAINED TRANSFORMED YEAST this declaration is of the following type:

- ☒ original
- ☐ design
- ☐ national stage of PCT.
- ☐ divisional
- ☐ continuation
- ☐ continuation-in-part (C-I-P)

the specification of which: *(complete (a), (b), or (c))*

(a) ☐ is attached hereto.

(b) ☒ was filed on September 23, 1998 as Application Serial No. 09/158,767 and was amended on *(if applicable)*.

(c) ☐ was described and claimed in PCT International Application No. filed on and was amended on *(if applicable)*.

Acknowledgement of Review of Papers and Duty of Candor

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of the subject matter claimed in this application in accordance with Title 37, Code of Federal Regulations § 1.56.

☐ In compliance with this duty there is attached an information disclosure statement. 37 CFR 1.98.

Priority Claim

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT International Application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT International Application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application on which priority is claimed

(complete (d) or (e))

(d) ☐ no such applications have been filed.

(e) ☒ such applications have been filed as follows:

PRIOR FOREIGN/PCT APPLICATION(S) FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION			
COUNTRY	APPLICATION NO.	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
FRANCE	97 12094	24-9-97	
			PRIORITY CLAIMED UNDER 35 USC 119
			[x] YES NO []
			[] YES NO []
			[] YES NO []
ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION			
			[] YES NO []
			[] YES NO []
			[] YES NO []

Claim for Benefit of Prior U.S. Provisional Application(s)

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

Provisional Application Number	Filing Date

Claim for Benefit of Earlier U.S./PCT Application(s) under 35 U.S.C. 120

(complete this part only if this is a divisional, continuation or C-I-P application)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information as defined in Title 37, Code of Federal Regulations, § 1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

Power of Attorney

As a named inventor, I hereby appoint Dana M. Raymond, Reg. No. 18,540; Frederick C. Carver, Reg. No. 17,021; Francis J. Hone, Reg. No. 18,662; Joseph D. Garon, Reg. No. 20,420; Arthur S. Tenser, Reg. No. 18,839; Ronald B. Hildreth, Reg. No. 19,498; Thomas R. Nesbitt, Jr., Reg. No. 22,075; Robert Neuner, Reg. No. 24,316; Richard G. Berkley, Reg. No. 25,465; Richard S. Clark, Reg. No. 26,154; Bradley B. Geist, Reg. No. 27,551; James J. Maune, Reg. No. 26,946; John D. Murnane, Reg. No. 29,836; Henry Tang, Reg. No. 29,705; Robert C. Scheinfeld, Reg. No. 31,300; John A. Fogarty, Jr., Reg. No. 22,348; Louis S. Sorell, Reg. No. 32,439 and Rochelle K. Seide Reg. No. 32,300 of the firm of BAKER & BOTTS, L.L.P., with offices at 30 Rockefeller Plaza, New York, New York 10112, as attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith

SEND CORRESPONDENCE TO: BAKER & BOTTS, L.L.P. 30 ROCKEFELLER PLAZA, NEW YORK, N.Y. 10112 CUSTOMER NUMBER: 21003	DIRECT TELEPHONE CALLS TO: BAKER & BOTTS, L.L.P. (212) 705-5000
---	--

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section

001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR	LAST NAME BATARD	FIRST NAME YANNICK	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY STRASBOURG	STATE or FOREIGN COUNTRY FRANCE	COUNTRY OF CITIZENSHIP FRANCE	
POST OFFICE ADDRESS	POST OFFICE ADDRESS 5, Rue de l'Aimant	CITY STRASBOURG	STATE or COUNTRY FRANCE	ZIP CODE 67000
DATE 19/01/99	SIGNATURE OF INVENTOR Yannick BATARD			
FULL NAME OF SECOND JOINT INVENTOR, IF ANY	LAST NAME DURST	FIRST NAME FRANCIS	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY BERNOLSHEIM	STATE or FOREIGN COUNTRY FRANCE	COUNTRY OF CITIZENSHIP FRANCE	
POST OFFICE ADDRESS	POST OFFICE ADDRESS 7, Rue de l'Ancienne Ecole	CITY BERNOLSHEIM	STATE or COUNTRY FRANCE	ZIP CODE 67170
DATE 01/20/99	SIGNATURE OF INVENTOR Francis DURST			
FULL NAME OF THIRD JOINT INVENTOR, IF ANY	LAST NAME SCHALK	FIRST NAME MICHEL	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY HUTTEHEIM	STATE or FOREIGN COUNTRY FRANCE	COUNTRY OF CITIZENSHIP FRANCE	
POST OFFICE ADDRESS	POST OFFICE ADDRESS 2, Rue de l'Ungersberg	CITY HUTTEHEIM	STATE or COUNTRY FRANCE	ZIP CODE 67230
DATE 12-02-99	SIGNATURE OF INVENTOR			
FULL NAME OF FOURTH JOINT INVENTOR, IF ANY	LAST NAME WERCK-REICHART	FIRST NAME DANIELE	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY DINGSHEIM	STATE or FOREIGN COUNTRY FRANCE	COUNTRY OF CITIZENSHIP FRANCE	
POST OFFICE ADDRESS	POST OFFICE ADDRESS 3, Rue de Bagdad	CITY DUNGSHEIM	STATE or COUNTRY FRANCE	ZIP CODE 67370
DATE 01/22/99	SIGNATURE OF INVENTOR Daniele WERCK-REICHART			
FULL NAME OF FIFTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY	ZIP CODE
DATE	SIGNATURE OF INVENTOR			
FULL NAME OF SIXTH JOINT INVENTOR, IF ANY	LAST NAME	FIRST NAME	MIDDLE NAME	
RESIDENCE & CITIZENSHIP	CITY	STATE or FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP	
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE or COUNTRY	ZIP CODE
DATE	SIGNATURE OF INVENTOR			

Figure 1 consists of 12 sub-graphs labeled (a) through (l), each showing the growth of *E. coli* O157:H7 in ground beef under different conditions. The y-axis for all graphs is \log_{10} CFU/g, ranging from 0 to 10. The x-axis is time in hours, ranging from 0 to 24. The graphs show various growth curves, including control, different temperatures, and different treatments.

- (a) Control: Shows a steady increase in bacterial count over time, reaching approximately 10 \log_{10} CFU/g by 24 hours.
- (b) 4°C: Shows a very slow increase in bacterial count, reaching approximately 1 \log_{10} CFU/g by 24 hours.
- (c) 10°C: Shows a slow increase in bacterial count, reaching approximately 2 \log_{10} CFU/g by 24 hours.
- (d) 15°C: Shows a moderate increase in bacterial count, reaching approximately 4 \log_{10} CFU/g by 24 hours.
- (e) 20°C: Shows a rapid increase in bacterial count, reaching approximately 8 \log_{10} CFU/g by 24 hours.
- (f) 25°C: Shows a very rapid increase in bacterial count, reaching approximately 10 \log_{10} CFU/g by 24 hours.
- (g) 30°C: Shows a very rapid increase in bacterial count, reaching approximately 10 \log_{10} CFU/g by 24 hours.
- (h) 35°C: Shows a very rapid increase in bacterial count, reaching approximately 10 \log_{10} CFU/g by 24 hours.
- (i) 40°C: Shows a very rapid increase in bacterial count, reaching approximately 10 \log_{10} CFU/g by 24 hours.
- (j) 45°C: Shows a very rapid increase in bacterial count, reaching approximately 10 \log_{10} CFU/g by 24 hours.
- (k) 50°C: Shows a very rapid increase in bacterial count, reaching approximately 10 \log_{10} CFU/g by 24 hours.
- (l) 55°C: Shows a very rapid increase in bacterial count, reaching approximately 10 \log_{10} CFU/g by 24 hours.

<120> RECODING OF DNA SEQUENCES PERMITTING
EXPRESSION IN YEAST AND OBTAINED TRANSFORMED YEAST

<140> 09/158,767

<150> FR 97-12094

<160> 20

<210> 1

<212> DNA

<213> Triticum aestivum

<400> 1

cgcagcacgg	caacacatac	acaggagcca	cacaccgcac	ctaccccgat	ggacgtcctc	60
ctcctggaga	aggccctcct	gggcctcttc	gccgcggcgg	tgctggccat	cgccgtcgcc	120
aagctcaccg	gcaagcgctt	ccgcctcccc	cctggccccct	cgggcgcccc	catcgtcggc	180
aactggctgc	aggtcggcga	cgacctcaac	caccgcaacc	tgatgggcct	ggccaagcgg	240
ttcggcgagg	tgttcctcct	ccgcatgggc	gtccgcaacc	tgggtggtcgt	ctccagcccc	300
gagctcgcca	aggaggtcct	ccacaccag	ggcgtcgagt	tcggctcccg	caccgcgaac	360
gtcgtcttcg	acatcttcac	cggcaaggga	caggacatgg	tgttcacggt	gtacggcgac	420
cactggcgca	agatgcggcg	gatcatgacg	gtgcccttct	tcaccaacaa	ggtggtggcg	480
cagaaccgcg	tgggggtgga	ggaggaggcc	cggctggtgg	tggaggacct	caaggccgac	540
ccggcgggcg	cgacggcggg	cgtggtggtc	cgccgcaggc	tgcagctcat	gatgtacaac	600
gacatgttcc	gcacatgtt	cgaccgcgg	ttcgagagcg	tggccgaccc	gctcttcaac	660
cagctcaagg	cgctcaacgc	cgagcgcagc	atcctctccc	agagcttcga	ctacaactac	720
ggcgacttca	tccccgtcct	ccgccccttc	ctccgcgcgt	acctcaaccg	ctgcaccaac	780
ctcaagacca	agcggatgaa	ggtgttcgag	gaccacttcg	tccagcagcg	caaggaggcg	840
ttggaqaaga	cqqqtgaqat	caqqtgcgcc	atggaccaca	tcctggaagc	cgaaaggaag	900

ggcgagatca	accacgacaa	cgtcctctac	atcgctcgaga	acatcaacgt	cgcagccatc	960
gagacgacgc	tgtggtcgat	cgagtggggc	ctcgcgaggc	tggatgaacca	cccggagatc	1020
cagcagaagc	tgcgcgagga	gatcgctgcc	gttctgggag	ccggcgtggc	ggtgacggag	1080
ccggacctgg	agcgctccc	ctacctgcag	tccgtggtga	aggagacgct	ccgcctccgc	1140
atggcaatcc	cgctcctggg	gccgcacatg	aacctcagcg	acgccaagct	cgccggctac	1200
gacatccccg	ccgagtcctc	gatcctcgct	aacgcctggg	tcctcgccaa	cgaccccaag	1260
cggtgggtgc	gcgcgcgatg	gttcaggccg	gagaggttcc	tcgaggagga	gaaggccgct	1320
gaggccacgc	gcaacgattt	ccggttcgtg	cccttcggcg	tcggccgccc	gagctgcccc	1380
gggatcatcc	tcgcgctgcc	catcatcggc	atcacgctcg	gacgcctggg	gcagaacttc	1440
cagctgctgc	cgccgcccgg	gcaggacaag	atcgacacca	ccgagaagcc	cgggcagttt	1500
accaaccaga	tcctcaagca	cgccaccatt	gtctgcaagc	cactcgaggc	ttactgaat	1560
tgaggtttcg	gtcatgggag	cccgtgacg	cggggagatg	gatctatgca	tgtgactgtg	1620
tattttgcct	tctttctttt	tggtgttggt	ttttgcagta	gtaagtttaa	tttttctttg	1680
gtgttgccct	atttgtcttc	atgtgaggcg	tcgtgttgta	aatttccata	tagttggcaa	1740
tgtgatgtaa	aacttggttc	caaaaaaaaa	aaaaaaaaaac	tcgagactct	tctctctctc	1800
tctctctctc	cagcctcggg	tctctgctgg	caaggggaact	tgcattaccc	tgtgtacgac	1860
ggcgccatgt	tcgtccctga	agcaccctcc	ctgcagagct	cccaggacaa	cttcgctgca	1920
tctgctgggt	tcaagcgctg	aaggagagag	ttttgaatac	ccgaaagaat	atagcggttg	1980
acatatctgt	caaacagggg	atcttgctgt	gggtctcttg	gtgggccaac	tcgcatagac	2040
aatcattcaa	atggatgggt	tcttcgctgg	tcggtcaaaa	agtatatgtt	gtaattgtac	2100
gccttttttg	ggtcttggtg	ccaaagatca	tggttattga	gttggtgagc	ctgagataac	2160
aggtttgtgt	atagtgaat	aaagaggagc	gtcgtaaca	ccatgtacta	tataggcttt	2220
gaaattccat	taagatgcat	cagaaatcaa	tggttgattt	g		2261

<210> 2
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic primer

<400> 2

atatatggat	ccatggacgt	cctcctcctg	gagaaggc	38
------------	------------	------------	----------	----

<210> 3
 <211> 56
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Synthetic primer

<400> 3

atatatggat	ccatggatgt	tttggtgttg	gagaaggccc	tcctgggcct	cttcgc	56
------------	------------	------------	------------	------------	--------	----

<210> 4
<211> 71
<212> DNA
<213> Triticum aestivum

<220>
<223> Synthetic primer

<400> 4
atatatggat ccatggatgt tttgttggtg gaaaaagctt tgttggggtt gttcgccgcg 60
gcggtgctgg c 71

<210> 5
<211> 143
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer

<400> 5
atatatggat ccatggatgt tttgttggtg gaaaaagctt tgttggggtt gtttgctgct 60
gctgttttgg ctattgctgt tgctaaattg actggtaaaa gatttagatt gccaccaggt 120
ccatccgcgcg ccccatcgt cgg 143

<210> 6
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic primer

<400> 6
tatatagaat tccagttaag cctcgagtgg ctgcagac 39

<210> 7
<211> 1506
<212> DNA
<213> Artificial Sequence

<220>
<223> Altered sequences

<400> 7

atggatgttt	tggtgttgga	gaaggccctc	ctgggcctct	tcgccgcggc	ggtgctggcc	60
atcgccgtcg	ccaagctcac	cggcaagcgc	ttccgcctcc	cccctggccc	ctccggcgcc	120
cccatcgtcg	gcaactggct	gcaggtcggc	gacgacctca	accaccgcaa	cctgatgggc	180
ctggccaagc	ggttcggcga	ggtgttcctc	ctccgcctgg	gcgtccgcaa	cctggtggtc	240
gtctccagcc	ccgagctcgc	caaggaggtc	ctccacaccc	agggcgtcga	gttcggctcc	300
cgcacccgca	acgtcgtctt	cgacatcttc	accggcaagg	gacaggacat	ggtgttcacg	360
gtgtacggcg	accactggcg	caagatgcgg	cggatcatga	cggtgccctt	cttcaccaac	420
aaggtggtgg	cgcagaaccg	cgtgggggtg	gaggaggagg	cccggctggt	ggtggaggac	480
ctcaaggccg	acccggcggc	ggcgacggcg	ggcgtggtgg	tccgccgcag	gctgcagctc	540
atgatgtaca	acgacatggt	ccgcatcatg	ttcgaccgcc	ggttcgagag	cgtggccgac	600
ccgctcttca	accagctcaa	ggcgtctaac	gccgagcgca	gcatcctctc	ccagagcttc	660
gactacaact	acggcgactt	catccccgtc	ctccgcccct	tcctccgcgg	ctacctcaac	720
cgctgcacca	acctcaagac	caagcggatg	aaggtgttcg	aggaccactt	cgtccagcag	780
cgcaaggagg	cgttgaggaa	gacgggtgag	atcaggtgcg	ccatggacca	catcctggaa	840
gccgaaagga	agggcgagat	caaccacgac	aacgtcctct	acatcgtcga	gaacatcaac	900
gtcgcagcca	tcgagacgac	gctgtggtcg	atcgagtggg	gcctcgcgga	gctggtgaac	960
cacccggaga	tccagcagaa	gctgcgcgag	gagatcgtcg	ccgttctggg	cgccggcgtg	1020
gcggtgacgg	agccggacct	ggagcgcctc	ccctacctgc	agtccgtggt	gaaggagacg	1080
ctccgcctcc	gcatggcaat	cccgtcctcg	gtgccgcaca	tgaacctcag	cgacgccaaag	1140
ctcgccggct	acgacatccc	cgccgagtcg	aagatcctcg	tcaacgcctg	gttcctcgcc	1200
aacgacccca	agcgggtgggt	gcgcgcgcgat	gagttcaggc	cggagagggt	cctcgaggag	1260
gagaaggccg	tcgaggccca	cggcaacgat	ttccggttcg	tgcccttcgg	cgtcggccgc	1320
cggagctgcc	ccgggatcat	cctcgcgctg	cccatcatcg	gcatcacgct	cggacgcctg	1380
gtgcagaact	tccagctgct	gccgccgcgg	gggcaggaca	agatcgacac	caccgagaag	1440
cccgggcagt	ttaccaacca	gatcctcaag	cacgccacca	ttgtctgcaa	gccactcgag	1500
gcttaa						1506

<210> 8

<211> 1506

<212> DNA

<213> Artificial Sequence

<220>

<223> Altered sequences

<400> 8

atggatgttt	tggtgttgga	aaaagctttg	ttgggtttgt	tcgccgcggc	ggtgctggcc	60
atcgccgtcg	ccaagctcac	cggcaagcgc	ttccgcctcc	cccctggccc	ctccggcgcc	120
cccatcgtcg	gcaactggct	gcaggtcggc	gacgacctca	accaccgcaa	cctgatgggc	180
ctggccaagc	ggttcggcga	ggtgttcctc	ctccgcctgg	gcgtccgcaa	cctggtggtc	240
gtctccagcc	ccgagctcgc	caaggaggtc	ctccacaccc	agggcgtcga	gttcggctcc	300
cgcacccgca	acgtcgtctt	cgacatcttc	accggcaagg	gacaggacat	ggtgttcacg	360
gtgtacggcg	accactggcg	caagatgcgg	cggatcatga	cggtgccctt	cttcaccaac	420
aaggtggtgg	cgcagaaccg	cgtgggggtg	gaggaggagg	cccggctggt	ggtggaggac	480
ctcaaggccg	acccggcggc	ggcgacggcg	ggcgtggtgg	tccgccgcag	gctgcagctc	540

atgatgtaca	acgacatggt	ccgcatcatg	ttcgaccgcc	ggttcgagag	cgtggccgac	600
ccgctcttca	accagctcaa	ggcgtcaac	gccgagcgca	gcaccccttc	ccagagcttc	660
gactacaact	acggcgactt	catccccgtc	ctccgcccct	tcctccgccc	ctacctcaac	720
cgctgcacca	acctcaagac	caagcggatg	aaggtgttcg	aggaccactt	cgtccagcag	780
cgcaaggagg	cgttggagaa	gacgggtgag	atcaggtgcg	ccatggacca	catcctggaa	840
gccgaaagga	agggcgagat	caaccacgac	aacgtcctct	acatcgtcga	gaacatcaac	900
gtcgcagcca	tcgagacgac	gctgtggtcg	atcgagtggg	gcctcgcgga	gctggtgaac	960
cacccggaga	tccagcagaa	gctgcgcgag	gagatcgtcg	ccgttctggg	cgccggcgtg	1020
gcggtgacgg	agccggacct	ggagcgcctc	ccctacctgc	agtccgtggg	gaaggagacg	1080
ctccgcctcc	gcatggcaat	cccgtcctcg	gtgccgcaca	tgaacctcag	cgacgccaag	1140
ctcgccggct	acgacatccc	cgccgagtcg	aagatcctcg	tcaacgcctg	gttcctcgcc	1200
aacgacccca	agcgggtggg	gcgcgcgat	gagttcaggc	cggagagggt	cctcgaggag	1260
gagaaggccg	tcgaggccca	cggcaacgat	ttccgggttc	tgcccttcgg	cgtcggccgc	1320
cggagctgcc	ccgggatcat	cctcgcgctg	cccatcatcg	gcacacgct	cggacgcctg	1380
gtgcagaact	tccagctgct	gccgcgcgcg	gggcaggaca	agatcgacac	caccgagaag	1440
cccgggcagt	ttaccaacca	gatcctcaag	cacgccacca	ttgtctgcaa	gccactcgag	1500
ggttaa						1506

<210> 9

<211> 1506

<212> DNA

<213> Artificial Sequence

<220>

<223> Altered sequences

<400> 9

atgggatgttt	tggtgttgga	aaaagctttg	ttgggtttgt	ttgctgctgc	tgttttggct	60
atgtgctgttg	ctaaattgac	tggtaaaaga	tttagattgc	caccagggtcc	atccggcgcc	120
cccacgctcg	gcaactggct	gcaggtcggc	gacgacctca	accaccgcaa	cctgatgggc	180
ctggccaagc	ggttcggcga	ggtgttcctc	ctccgcatgg	gcgtccgcaa	cctggtggct	240
gtctccagcc	ccgagctcgc	caaggaggct	ctccacaccc	agggcgctcg	gttcggctcc	300
cgcacccgca	acgtcgtctt	cgacatcttc	accggcaagg	gacaggacat	ggtgttcacg	360
gtgtacggcg	accactggcg	caagatgctg	cggatcatga	cgggtgccctt	cttcaccaac	420
aaggtggtgg	cgcagaaccg	cgtgggggtg	gaggaggagg	cccggctggg	ggtggaggac	480
ctcaaggccg	accggcgggc	ggcgacggcg	ggcgtggtgg	tcgcgcgcag	gctgcagctc	540
atgatgtaca	acgacatggt	ccgcatcatg	ttcgaccgcc	ggttcgagag	cgtggccgac	600
ccgctcttca	accagctcaa	ggcgtcaac	gccgagcgca	gcaccccttc	ccagagcttc	660
gactacaact	acggcgactt	catccccgtc	ctccgcccct	tcctccgccc	ctacctcaac	720
cgctgcacca	acctcaagac	caagcggatg	aaggtgttcg	aggaccactt	cgtccagcag	780
cgcaaggagg	cgttggagaa	gacgggtgag	atcaggtgcg	ccatggacca	catcctggaa	840
gccgaaagga	agggcgagat	caaccacgac	aacgtcctct	acatcgtcga	gaacatcaac	900
gtcgcagcca	tcgagacgac	gctgtggtcg	atcgagtggg	gcctcgcgga	gctggtgaac	960
cacccggaga	tccagcagaa	gctgcgcgag	gagatcgtcg	ccgttctggg	cgccggcgtg	1020
gcggtgacgg	agccggacct	ggagcgcctc	ccctacctgc	agtccgtggg	gaaggagacg	1080

ctcgcctcc	gcatggcaat	cccgtcctg	gtgccgcaca	tgaacctcag	cgacgccaaag	1140
ctcgccggct	acgacatccc	cgccgagtcc	aagatccctg	tcaacgcctg	gttcctcgcc	1200
aacgacccca	agcgggtgggt	gcgcgccgat	gagttcaggc	cggagagggt	cctcgaggag	1260
gagaaggccg	tcgaggccca	cggcaacgat	ttccggttcg	tgcccttcgg	cgtcggccgc	1320
cggagctgcc	cgggatcat	cctcgcgctg	cccatcatcg	gcatcacgct	cggacgcctg	1380
gtgcagaact	tccagctgct	gccgccgccg	gggcaggaca	agatcgacac	caccgagaag	1440
cccgggcagt	ttaccaacca	gacctcaag	cacgccacca	ttgtctgcaa	gccactcgag	1500
gcttaa						1506

<210> 10

<211> 2181

<212> DNA

<213> *Triticum aestivum*

<400> 10

cgatccaccc	cttggatcca	ctctaccacg	ctcgctagcc	agcgggggtac	atacacgcac	60
gcacgtacgc	gcgtacgtac	actcgcagag	cttgcttcag	ggaggccggc	aatggagggtg	120
gggacgtggg	cgggtgggtg	gtcggcggtg	gccgcgtaca	tggcgtgggt	ctggcggatg	180
tcccgcgggc	tgcgcggggc	gcgggttttg	cccgtgctcg	gcagcctgcc	gggcctgggtg	240
cagcacgccg	aggacatgca	cgagtggatc	gccggcaacc	tgcgccgcgc	gggcggcacg	300
taccagacct	gcatcttcgc	cgtgcccggg	gtggcgcgcc	gcggcggcct	ggtcaccgtc	360
acctgcgacc	cgcgcaacct	ggagcacgtc	ctgaaggcgc	gcttcgacaa	ctaccccaag	420
ggccccttct	ggcacggcgt	cttcggggac	ctgctcggcg	acggcatctt	caattccgac	480
ggcgacacct	ggctcgcgca	gcgcaagacg	gccgcgctcg	agttcaccac	ccgcacgctc	540
cggacggcca	tgtcccgtcg	ggtctcgcgc	tccatccacg	gccgcctcct	gcccacctcg	600
gccgacgcgg	ccaagggcaa	ggcgcagggtg	gatctccagg	acctcctcct	ccgcctcacc	660
ttcgacaaca	tctgcggcct	ggccttcggc	aaggaccggg	agacgctcgc	ccagggcctg	720
cgggagaacg	agttcgcttc	cgcgttcgac	cgcgccaccg	aggccacgct	caaccgcttc	780
atcttcccgg	agttcctgtg	gcgctgcaaa	aagtggctgg	gcctcggcct	ggagaccacg	840
ctgaccagca	gcatggccca	cgtcgaccag	tacctcgccg	ccgtcatcaa	gaagcgcaag	900
ctcgagctcg	ccgccggcaa	cggcaaatgc	gacacggcgg	cgacgcacga	cgacctgctc	960
tcccggttca	tgcggaaggg	ttcctactcg	gacgagtcgc	tccagcacgt	ggcgctcaac	1020
ttcactctcg	ccggccgcga	cacctcctcc	gtggcgctct	cctggttctt	ctggctcggtg	1080
tccaccacc	ctgcggtgga	gcgcaagatc	gtgcgcgagc	tctgctccgt	tctcgccgcg	1140
tcacggggcg	cccatgaccc	ggcattgtgg	ctggcggagc	ccttcacctt	cgaggagctc	1200
gaccgcctgg	tctacctcaa	ggcggcgctg	tcggagaccc	tccgcctcta	cccctccgtc	1260
cccgaggact	ccaagcacgt	cgtcgcggac	gactacctcc	ccgacggcac	cttcgtgccg	1320
gccgggtcgt	cggtcaccta	ctccatatac	tcggcggggc	gcatgaaggg	ggtgtggggg	1380
gaggactgcc	tcgagttccg	gccggagcga	tggctgtcgg	ccgacggcac	caagttcgag	1440
cagcacgact	cgtacaagtt	cgtggcgctc	aacgccgggc	cgagggtgtg	cctgggcaag	1500
gacctagcct	acctgcagat	gaagaacatc	gccgggagcg	tgctgctcgg	gcaccgctcg	1560
accgtggcgc	cgggccaccg	cgtggagcag	aagatgtcgc	tcacgctctt	catgaagggc	1620
gggctacgga	tggaggtacg	tccgcgcgac	ctcgcccccg	tcctcgacga	gccctgcggc	1680
ctggacgccg	gcgccgccac	cgcgcgccga	gcaagtgccca	cagcgccgtg	cgcgtagaag	1740
acctggcacc	ggcacgcgcc	atgcatgatt	cgtgcgtgct	agctgttgaa	gggacgccgg	1800

acattgaatg	tgtagatagg	gcagcagtgc	aagaccgtaa	gtaaaattga	tgatggggtt	1860
ggtgacaaca	ttgaagccac	tcctttccag	aattttacgac	ccggatagga	gaaacagggg	1920
aactttgcag	atcacaacac	aagatctagc	cagccgggga	tctgatctga	tttgcgtctg	1980
ctcggagcac	gggtgcatgg	gagaccaagg	aggaaaacaa	aaaataacag	aaacagagtg	2040
agcaatattt	gtgattgtag	ccacgggaaa	gagagaggag	taattagtaa	ttcagatttg	2100
tttgcagtag	ctcggtggtg	gtgaccagat	catagccaac	taggctattc	tattctattc	2160
tatttttgaa	gatgattttt	c				2181

<210> 11

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer

<400> 11

at	atatggat	ccatggaggt	ggggacgtgg	gcggtggtg	39
----	----------	------------	------------	-----------	----

<210> 12

<211> 150

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer

<400> 12

at	atatggat	ccatggaagt	tggtacttgg	gctggtggtg	tttctgctgt	tgctgcttat	60
at	ggcttggt	tttggagaat	gtctagaggt	ttgagaggtc	caagagtttg	gccagttttg	120
gg	ttccttgc	caggcctggt	gcagcacgcc				150

<210> 13

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic primer

<400> 13

t	atatagaat	tccttctacg	cgcacggcgc	tgtggcactt	gc	42
---	-----------	------------	------------	------------	----	----

<210> 14

<211> 1626

<212> DNA

<213> Artificial Sequence

<220>

<223> Altered sequences

<400> 14

atggaagtgtg	gtacttgggc	tggttgttgtt	tctgctgttg	ctgcttatat	ggcttggttt	60
tggagaatgt	ctagaggttt	gagaggtcca	agagtttggc	cagttttggg	ttctttgcca	120
ggcctgggtgc	agcacgccga	ggacatgcac	gagtggatcg	ccggcaacct	gcgccgcgcg	180
ggcggcacgt	accagacctg	catcttcgcc	gtgcccgggg	tggcgcgcgcg	cggcggcctg	240
gtcaccgtca	cctgcgaccc	gcgcaacctg	gagcacgtcc	tgaaggcgcg	cttcgacaac	300
taccccaagg	gccccttctg	gcacggcgctc	ttccgggacc	tgctcggcga	cggcatcttc	360
aattccgacg	gcgacacctg	gctcgcgcag	cgcaagacgg	cgcgcgtcga	gttcaccacc	420
cgcacgctcc	ggacggccat	gtcccgcgtg	gtctcgcgct	ccatccacgg	ccgcctcctg	480
cccacctctg	ccgacgcggc	caagggcaag	gcgcaggtgg	atctccagga	cctcctcctc	540
cgcctcacct	tcgacaacat	ctgcggcctg	gccttcggca	aggacccgga	gacgctcgcc	600
cagggcctgc	cggagaacga	gttcgcctcc	gcgttcgacc	gcgccaccga	ggccacgctc	660
aaccgcttca	tcttcccgga	gttcctgtgg	cgctgcaaaa	agtggctggg	cctcggcatg	720
gagaccacgc	tgaccagcag	catggcccac	gtcgaccagt	acctcgcgcg	cgtcatcaag	780
aagcgcaagc	tcgagctcgc	cgccggcaac	ggcaaatgcg	acacggcggc	gacgcacgac	840
gacctgctct	cccggttcat	gcggaagggt	tcctactcgg	acgagtcgct	ccagcacgtg	900
gcgctcaact	tcacctctgc	cggccgcgac	acctcctccg	tggcgcctctc	ctggttcttc	960
tggctcgtgt	ccaccacccc	tgcggtggag	cgcaagatcg	tgcgcgagct	ctgctccgtt	1020
ctcgcgcgct	cacggggcgc	ccatgacccg	gcattgtggc	tggcggagcc	cttcaccttc	1080
gaggagctcg	accgcctggt	ctacctcaag	gcggcgcgtg	cggagaccct	ccgcctctac	1140
ccctccgtcc	ccgaggactc	caagcacgtc	gtcgcggacg	actacctccc	cgacggcacc	1200
ttcgtgccgg	ccgggtcgctc	ggtcacctac	tccatatact	cggcggggcg	catgaagggg	1260
gtgtgggggg	aggactgcct	cgagttccgg	ccggagcgat	ggctgtcggc	cgacggcacc	1320
aagtccgagc	agcacgactc	gtacaagttc	gtggcgttca	acgccggggc	gaggggtgtgc	1380
ctgggcaagg	acctagccta	cctgcagatg	aagaacatcg	ccgggagcgt	gctgctccgg	1440
caccgcctga	ccgtggcgcc	gggccaccgc	gtggagcaga	agatgtcgtc	cacgctcttc	1500
atgaagggcg	ggctacggat	ggaggtacgt	ccgcgcgacc	tcgcccccg	cctcgacgag	1560
ccctgcggcc	tggacgcggg	cgccgccacc	gccgccgcag	caagtgccac	agcgcctgtc	1620
gcgtag						1626

<210> 15

<211> 501

<212> PRT

<213> Artificial Sequence

<220>

<223> Altered sequences

<400> 15

Met	Asp	Val	Leu	Leu	Leu	Glu	Lys	Ala	Leu	Leu	Gly	Leu	Phe	Ala	Ala
1				5					10					15	
Ala	Val	Leu	Ala	Ile	Ala	Val	Ala	Lys	Leu	Thr	Gly	Lys	Arg	Phe	Arg
			20					25					30		
Leu	Pro	Pro	Gly	Pro	Ser	Gly	Ala	Pro	Ile	Val	Gly	Asn	Trp	Leu	Gln
		35					40					45			
Val	Gly	Asp	Asp	Leu	Asn	His	Arg	Asn	Leu	Met	Gly	Leu	Ala	Lys	Arg
	50					55					60				
Phe	Gly	Glu	Val	Phe	Leu	Leu	Arg	Met	Gly	Val	Arg	Asn	Leu	Val	Val
65					70					75					80
Val	Ser	Ser	Pro	Glu	Leu	Ala	Lys	Glu	Val	Leu	His	Thr	Gln	Gly	Val
				85					90					95	
Glu	Phe	Gly	Ser	Arg	Thr	Arg	Asn	Val	Val	Phe	Asp	Ile	Phe	Thr	Gly
			100					105						110	
Lys	Gly	Gln	Asp	Met	Val	Phe	Thr	Val	Tyr	Gly	Asp	His	Trp	Arg	Lys
		115					120					125			
Met	Arg	Arg	Ile	Met	Thr	Val	Pro	Phe	Phe	Thr	Asn	Lys	Val	Val	Ala
	130					135					140				
Gln	Asn	Arg	Val	Gly	Trp	Glu	Glu	Glu	Ala	Arg	Leu	Val	Val	Glu	Asp
145					150					155					160
Leu	Lys	Ala	Asp	Pro	Ala	Ala	Ala	Thr	Ala	Gly	Val	Val	Val	Arg	Arg
				165					170					175	
Arg	Leu	Gln	Leu	Met	Met	Tyr	Asn	Asp	Met	Phe	Arg	Ile	Met	Phe	Asp
			180					185					190		
Arg	Arg	Phe	Glu	Ser	Val	Ala	Asp	Pro	Leu	Phe	Asn	Gln	Leu	Lys	Ala
		195				200						205			
Leu	Asn	Ala	Glu	Arg	Ser	Ile	Leu	Ser	Gln	Ser	Phe	Asp	Tyr	Asn	Tyr
	210					215					220				
Gly	Asp	Phe	Ile	Pro	Val	Leu	Arg	Pro	Phe	Leu	Arg	Arg	Tyr	Leu	Asn
225					230					235					240
Arg	Cys	Thr	Asn	Leu	Lys	Thr	Lys	Arg	Met	Lys	Val	Phe	Glu	Asp	His
			245					250					255		
Phe	Val	Gln	Gln	Arg	Lys	Glu	Ala	Leu	Glu	Lys	Thr	Gly	Glu	Ile	Arg
			260					265					270		
Cys	Ala	Met	Asp	His	Ile	Leu	Glu	Ala	Glu	Arg	Lys	Gly	Glu	Ile	Asn
		275				280						285			
His	Asp	Asn	Val	Leu	Tyr	Ile	Val	Glu	Asn	Ile	Asn	Val	Ala	Ala	Ile
	290					295					300				
Glu	Thr	Thr	Leu	Trp	Ser	Ile	Glu	Trp	Gly	Leu	Ala	Glu	Leu	Val	Asn
305					310					315					320
His	Pro	Glu	Ile	Gln	Gln	Lys	Leu	Arg	Glu	Glu	Ile	Val	Ala	Val	Leu
				325				330					335		
Gly	Ala	Gly	Val	Ala	Val	Thr	Glu	Pro	Asp	Leu	Glu	Arg	Leu	Pro	Tyr

Leu	Gln	Ser	Val	Val	Lys	Glu	Thr	Leu	Arg	Leu	Arg	Met	Ala	Ile	Pro
		355					360					365			
Leu	Leu	Val	Pro	His	Met	Asn	Leu	Ser	Asp	Ala	Lys	Leu	Ala	Gly	Tyr
	370					375					380				
Asp	Ile	Pro	Ala	Glu	Ser	Lys	Ile	Leu	Val	Asn	Ala	Trp	Phe	Leu	Ala
385					390					395					400
Asn	Asp	Pro	Lys	Arg	Trp	Val	Arg	Ala	Asp	Glu	Phe	Arg	Pro	Glu	Arg
			405					410						415	
Phe	Leu	Glu	Glu	Glu	Lys	Ala	Val	Glu	Ala	His	Gly	Asn	Asp	Phe	Arg
		420						425					430		
Phe	Val	Pro	Phe	Gly	Val	Gly	Arg	Arg	Ser	Cys	Pro	Gly	Ile	Ile	Leu
	435					440						445			
Ala	Leu	Pro	Ile	Ile	Gly	Ile	Thr	Leu	Gly	Arg	Leu	Val	Gln	Asn	Phe
450					455						460				
Gln	Leu	Leu	Pro	Pro	Pro	Gly	Gln	Asp	Lys	Ile	Asp	Thr	Thr	Glu	Lys
465					470				475						480
Pro	Gly	Gln	Phe	Thr	Asn	Gln	Ile	Leu	Lys	His	Ala	Thr	Ile	Val	Cys
				485				490						495	
Lys	Pro	Leu	Glu	Ala											
			500												

<210> 16

<211> 501

<212> PRT

<213> Artificial Sequence

<220>

<223> Altered sequences

<400> 16

Met	Asp	Val	Leu	Leu	Leu	Glu	Lys	Ala	Leu	Leu	Gly	Leu	Phe	Ala	Ala
1			5					10					15		
Ala	Val	Leu	Ala	Ile	Ala	Val	Ala	Lys	Leu	Thr	Gly	Lys	Arg	Phe	Arg
		20					25					30			
Leu	Pro	Pro	Gly	Pro	Ser	Gly	Ala	Pro	Ile	Val	Gly	Asn	Trp	Leu	Gln
	35					40						45			
Val	Gly	Asp	Asp	Leu	Asn	His	Arg	Asn	Leu	Met	Gly	Leu	Ala	Lys	Arg
50					55					60					
Phe	Gly	Glu	Val	Phe	Leu	Leu	Arg	Met	Gly	Val	Arg	Asn	Leu	Val	Val
65				70					75					80	
Val	Ser	Ser	Pro	Glu	Leu	Ala	Lys	Glu	Val	Leu	His	Thr	Gln	Gly	Val
			85				90						95		
Glu	Phe	Gly	Ser	Arg	Thr	Arg	Asn	Val	Val	Phe	Asp	Ile	Phe	Thr	Gly
			100				105						110		
Lys	Gly	Gln	Asp	Met	Val	Phe	Thr	Val	Tyr	Gly	Asp	His	Trp	Arg	Lys

			115				120					125				
Met	Arg	Arg	Ile	Met	Thr	Val	Pro	Phe	Phe	Thr	Asn	Lys	Val	Val	Ala	
	130						135				140					
Gln	Asn	Arg	Val	Gly	Trp	Glu	Glu	Glu	Ala	Arg	Leu	Val	Val	Glu	Asp	
145					150					155					160	
Leu	Lys	Ala	Asp	Pro	Ala	Ala	Ala	Thr	Ala	Gly	Val	Val	Val	Arg	Arg	
				165					170						175	
Arg	Leu	Gln	Leu	Met	Met	Tyr	Asn	Asp	Met	Phe	Arg	Ile	Met	Phe	Asp	
			180					185					190			
Arg	Arg	Phe	Glu	Ser	Val	Ala	Asp	Pro	Leu	Phe	Asn	Gln	Leu	Lys	Ala	
	195						200					205				
Leu	Asn	Ala	Glu	Arg	Ser	Ile	Leu	Ser	Gln	Ser	Phe	Asp	Tyr	Asn	Tyr	
	210					215					220					
Gly	Asp	Phe	Ile	Pro	Val	Leu	Arg	Pro	Phe	Leu	Arg	Arg	Tyr	Leu	Asn	
225					230					235					240	
Arg	Cys	Thr	Asn	Leu	Lys	Thr	Lys	Arg	Met	Lys	Val	Phe	Glu	Asp	His	
				245					250					255		
Phe	Val	Gln	Gln	Arg	Lys	Glu	Ala	Leu	Glu	Lys	Thr	Gly	Glu	Ile	Arg	
			260					265					270			
Cys	Ala	Met	Asp	His	Ile	Leu	Glu	Ala	Glu	Arg	Lys	Gly	Glu	Ile	Asn	
	275						280					285				
His	Asp	Asn	Val	Leu	Tyr	Ile	Val	Glu	Asn	Ile	Asn	Val	Ala	Ala	Ile	
	290					295					300					
Glu	Thr	Thr	Leu	Trp	Ser	Ile	Glu	Trp	Gly	Leu	Ala	Glu	Leu	Val	Asn	
305					310					315					320	
His	Pro	Glu	Ile	Gln	Gln	Lys	Leu	Arg	Glu	Glu	Ile	Val	Ala	Val	Leu	
				325					330					335		
Gly	Ala	Gly	Val	Ala	Val	Thr	Glu	Pro	Asp	Leu	Glu	Arg	Leu	Pro	Tyr	
			340					345					350			
Leu	Gln	Ser	Val	Val	Lys	Glu	Thr	Leu	Arg	Leu	Arg	Met	Ala	Ile	Pro	
	355						360					365				
Leu	Leu	Val	Pro	His	Met	Asn	Leu	Ser	Asp	Ala	Lys	Leu	Ala	Gly	Tyr	
	370					375					380					
Asp	Ile	Pro	Ala	Glu	Ser	Lys	Ile	Leu	Val	Asn	Ala	Trp	Phe	Leu	Ala	
385					390					395					400	
Asn	Asp	Pro	Lys	Arg	Trp	Val	Arg	Ala	Asp	Glu	Phe	Arg	Pro	Glu	Arg	
				405					410					415		
Phe	Leu	Glu	Glu	Glu	Lys	Ala	Val	Glu	Ala	His	Gly	Asn	Asp	Phe	Arg	
			420					425					430			
Phe	Val	Pro	Phe	Gly	Val	Gly	Arg	Arg	Ser	Cys	Pro	Gly	Ile	Ile	Leu	
	435						440					445				
Ala	Leu	Pro	Ile	Ile	Gly	Ile	Thr	Leu	Gly	Arg	Leu	Val	Gln	Asn	Phe	
	450															

Pro Gly Gln Phe Thr Asn Gln Ile Leu Lys His Ala Thr Ile Val Cys
 485 490 495
 Lys Pro Leu Glu Ala
 500

<210> 17
 <211> 501
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Altered sequences

<400> 17
 Met Asp Val Leu Leu Leu Glu Lys Ala Leu Leu Gly Leu Phe Ala Ala
 1 5 10 15
 Ala Val Leu Ala Ile Ala Val Ala Lys Leu Thr Gly Lys Arg Phe Arg
 20 25 30
 Leu Pro Pro Gly Pro Ser Gly Ala Pro Ile Val Gly Asn Trp Leu Gln
 35 40 45
 Val Gly Asp Asp Leu Asn His Arg Asn Leu Met Gly Leu Ala Lys Arg
 50 55 60
 Phe Gly Glu Val Phe Leu Leu Arg Met Gly Val Arg Asn Leu Val Val
 65 70 75 80
 Val Ser Ser Pro Glu Leu Ala Lys Glu Val Leu His Thr Gln Gly Val
 85 90 95
 Glu Phe Gly Ser Arg Thr Arg Asn Val Val Phe Asp Ile Phe Thr Gly
 100 105 110
 Lys Gly Gln Asp Met Val Phe Thr Val Tyr Gly Asp His Trp Arg Lys
 115 120 125
 Met Arg Arg Ile Met Thr Val Pro Phe Phe Thr Asn Lys Val Val Ala
 130 135 140
 Gln Asn Arg Val Gly Trp Glu Glu Glu Ala Arg Leu Val Val Glu Asp
 145 150 155 160
 Leu Lys Ala Asp Pro Ala Ala Ala Thr Ala Gly Val Val Val Arg Arg
 165 170 175
 Arg Leu Gln Leu Met Met Tyr Asn Asp Met Phe Arg Ile Met Phe Asp
 180 185 190
 Arg Arg Phe Glu Ser Val Ala Asp Pro Leu Phe Asn Gln Leu Lys Ala
 195 200 205
 Leu Asn Ala Glu Arg Ser Ile Leu Ser Gln Ser Phe Asp Tyr Asn Tyr
 210 215 220
 Gly Asp Phe Ile Pro Val Leu Arg Pro Phe Leu Arg Arg Tyr Leu Asn
 225 230 235 240
 Arg Cys Thr Asn Leu Lys Thr Lys Arg Met Lys Val Phe Glu Asp His

				245				250					255			
Phe	Val	Gln	Gln	Arg	Lys	Glu	Ala	Leu	Glu	Lys	Thr	Gly	Glu	Ile	Arg	
			260					265					270			
Cys	Ala	Met	Asp	His	Ile	Leu	Glu	Ala	Glu	Arg	Lys	Gly	Glu	Ile	Asn	
		275						280				285				
His	Asp	Asn	Val	Leu	Tyr	Ile	Val	Glu	Asn	Ile	Asn	Val	Ala	Ala	Ile	
		290				295					300					
Glu	Thr	Thr	Leu	Trp	Ser	Ile	Glu	Trp	Gly	Leu	Ala	Glu	Leu	Val	Asn	
305					310					315					320	
His	Pro	Glu	Ile	Gln	Gln	Lys	Leu	Arg	Glu	Glu	Ile	Val	Ala	Val	Leu	
				325					330					335		
Gly	Ala	Gly	Val	Ala	Val	Thr	Glu	Pro	Asp	Leu	Glu	Arg	Leu	Pro	Tyr	
			340					345					350			
Leu	Gln	Ser	Val	Val	Lys	Glu	Thr	Leu	Arg	Leu	Arg	Met	Ala	Ile	Pro	
		355					360					365				
Leu	Leu	Val	Pro	His	Met	Asn	Leu	Ser	Asp	Ala	Lys	Leu	Ala	Gly	Tyr	
		370				375					380					
Asp	Ile	Pro	Ala	Glu	Ser	Lys	Ile	Leu	Val	Asn	Ala	Trp	Phe	Leu	Ala	
385					390					395					400	
Asn	Asp	Pro	Lys	Arg	Trp	Val	Arg	Ala	Asp	Glu	Phe	Arg	Pro	Glu	Arg	
			405					410					415			
Phe	Leu	Glu	Glu	Glu	Lys	Ala	Val	Glu	Ala	His	Gly	Asn	Asp	Phe	Arg	
			420					425					430			
Phe	Val	Pro	Phe	Gly	Val	Gly	Arg	Arg	Ser	Cys	Pro	Gly	Ile	Ile	Leu	
		435					440					445				
Ala	Leu	Pro	Ile	Ile	Gly	Ile	Thr	Leu	Gly	Arg	Leu	Val	Gln	Asn	Phe	
		450				455					460					
Gln	Leu	Leu	Pro	Pro	Pro	Gly	Gln	Asp	Lys	Ile	Asp	Thr	Thr	Glu	Lys	
465					470					475					480	
Pro	Gly	Gln	Phe	Thr	Asn	Gln	Ile	Leu	Lys	His	Ala	Thr	Ile	Val	Cys	
			485					490						495		
Lys	Pro	Leu	Glu	Ala												
			500													

<210> 18
 <211> 501
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Altered sequences

<400> 18

Met	Asp	Val	Leu	Leu	Glu	Lys	Ala	Leu	Leu	Gly	Leu	Phe	Ala	Ala		
1			5					10				15				

Ala	Val	Leu	Ala	Ile	Ala	Val	Ala	Lys	Leu	Thr	Gly	Lys	Arg	Phe	Arg
		20						25					30		
Leu	Pro	Pro	Gly	Pro	Ser	Gly	Ala	Pro	Ile	Val	Gly	Asn	Trp	Leu	Gln
		35					40					45			
Val	Gly	Asp	Asp	Leu	Asn	His	Arg	Asn	Leu	Met	Gly	Leu	Ala	Lys	Arg
	50					55					60				
Phe	Gly	Glu	Val	Phe	Leu	Leu	Arg	Met	Gly	Val	Arg	Asn	Leu	Val	Val
65					70					75					80
Val	Ser	Ser	Pro	Glu	Leu	Ala	Lys	Glu	Val	Leu	His	Thr	Gln	Gly	Val
				85					90					95	
Glu	Phe	Gly	Ser	Arg	Thr	Arg	Asn	Val	Val	Phe	Asp	Ile	Phe	Thr	Gly
			100					105					110		
Lys	Gly	Gln	Asp	Met	Val	Phe	Thr	Val	Tyr	Gly	Asp	His	Trp	Arg	Lys
		115					120					125			
Met	Arg	Arg	Ile	Met	Thr	Val	Pro	Phe	Phe	Thr	Asn	Lys	Val	Val	Ala
	130					135					140				
Gln	Asn	Arg	Val	Gly	Trp	Glu	Glu	Glu	Ala	Arg	Leu	Val	Val	Glu	Asp
145					150					155					160
Leu	Lys	Ala	Asp	Pro	Ala	Ala	Ala	Thr	Ala	Gly	Val	Val	Val	Arg	Arg
				165					170					175	
Arg	Leu	Gln	Leu	Met	Met	Tyr	Asn	Asp	Met	Phe	Arg	Ile	Met	Phe	Asp
			180					185					190		
Arg	Arg	Phe	Glu	Ser	Val	Ala	Asp	Pro	Leu	Phe	Asn	Gln	Leu	Lys	Ala
		195					200					205			
Leu	Asn	Ala	Glu	Arg	Ser	Ile	Leu	Ser	Gln	Ser	Phe	Asp	Tyr	Asn	Tyr
	210					215					220				
Gly	Asp	Phe	Ile	Pro	Val	Leu	Arg	Pro	Phe	Leu	Arg	Arg	Tyr	Leu	Asn
225					230					235					240
Arg	Cys	Thr	Asn	Leu	Lys	Thr	Lys	Arg	Met	Lys	Val	Phe	Glu	Asp	His
			245						250					255	
Phe	Val	Gln	Gln	Arg	Lys	Glu	Ala	Leu	Glu	Lys	Thr	Gly	Glu	Ile	Arg
			260					265					270		
Cys	Ala	Met	Asp	His	Ile	Leu	Glu	Ala	Glu	Arg	Lys	Gly	Glu	Ile	Asn
		275					280					285			
His	Asp	Asn	Val	Leu	Tyr	Ile	Val	Glu	Asn	Ile	Asn	Val	Ala	Ala	Ile
	290					295					300				
Glu	Thr	Thr	Leu	Trp	Ser	Ile	Glu	Trp	Gly	Leu	Ala	Glu	Leu	Val	Asn
305					310					315					320
His	Pro	Glu	Ile	Gln	Gln	Lys	Leu	Arg	Glu	Glu	Ile	Val	Ala	Val	Leu
				325					330					335	
Gly	Ala	Gly	Val	Ala	Val	Thr	Glu	Pro	Asp	Leu	Glu	Arg	Leu	Pro	Tyr
			340					345					350		
Leu	Gln	Ser	Val	Val	Lys	Glu									

370	375	380
Asp Ile Pro Ala Glu Ser Lys Ile Leu Val Asn Ala Trp Phe Leu Ala		
385	390	395
Asn Asp Pro Lys Arg Trp Val Arg Ala Asp Glu Phe Arg Pro Glu Arg		400
	405	410
Phe Leu Glu Glu Glu Lys Ala Val Glu Ala His Gly Asn Asp Phe Arg		415
	420	425
Phe Val Pro Phe Gly Val Gly Arg Arg Ser Cys Pro Gly Ile Ile Leu		430
	435	440
Ala Leu Pro Ile Ile Gly Ile Thr Leu Gly Arg Leu Val Gln Asn Phe		445
	450	455
Gln Leu Leu Pro Pro Pro Gly Gln Asp Lys Ile Asp Thr Thr Glu Lys		460
465	470	475
Pro Gly Gln Phe Thr Asn Gln Ile Leu Lys His Ala Thr Ile Val Cys		480
	485	490
Lys Pro Leu Glu Ala		495
	500	

- <210> 19
- <211> 541
- <212> PRT
- <213> Artificial Sequence
- <220>
- <223> Altered sequences

<400> 19

Met Glu Val Gly Thr Trp Ala Val Val Val Ser Ala Val Ala Ala Tyr		
1	5	10
Met Ala Trp Phe Trp Arg Met Ser Arg Gly Leu Arg Gly Pro Arg Val		15
	20	25
Trp Pro Val Leu Gly Ser Leu Pro Gly Leu Val Gln His Ala Glu Asp		30
	35	40
Met His Glu Trp Ile Ala Gly Asn Leu Arg Arg Ala Gly Gly Thr Tyr		45
	50	55
Gln Thr Cys Ile Phe Ala Val Pro Gly Val Ala Arg Arg Gly Gly Leu		60
65	70	75
Val Thr Val Thr Cys Asp Pro Arg Asn Leu Glu His Val Leu Lys Ala		80
	85	90
Arg Phe Asp Asn Tyr Pro Lys Gly Pro Phe Trp His Gly Val Phe Arg		95
	100	105
Asp Leu Leu Gly Asp Gly Ile Phe Asn Ser Asp Gly Asp Thr Trp Leu		110
	115	120
Ala Gln Arg Lys Thr Ala Ala Leu Glu Phe Thr Thr Arg Thr Leu Arg		125
	130	135
		140

Sequence

Thr	Ala	Met	Ser	Arg	Trp	Val	Ser	Arg	Ser	Ile	His	Gly	Arg	Leu	Leu
145					150					155					160
Pro	Ile	Leu	Ala	Asp	Ala	Ala	Lys	Gly	Lys	Ala	Gln	Val	Asp	Leu	Gln
				165					170					175	
Asp	Leu	Leu	Leu	Arg	Leu	Thr	Phe	Asp	Asn	Ile	Cys	Gly	Leu	Ala	Phe
				180				185					190		
Gly	Lys	Asp	Pro	Glu	Thr	Leu	Ala	Gln	Gly	Leu	Pro	Glu	Asn	Glu	Phe
		195					200					205			
Ala	Ser	Ala	Phe	Asp	Arg	Ala	Thr	Glu	Ala	Thr	Leu	Asn	Arg	Phe	Ile
	210					215					220				
Phe	Pro	Glu	Phe	Leu	Trp	Arg	Cys	Lys	Lys	Trp	Leu	Gly	Leu	Gly	Met
225					230					235					240
Glu	Thr	Thr	Leu	Thr	Ser	Ser	Met	Ala	His	Val	Asp	Gln	Tyr	Leu	Ala
				245					250					255	
Ala	Val	Ile	Lys	Lys	Arg	Lys	Leu	Glu	Leu	Ala	Ala	Gly	Asn	Gly	Lys
			260					265					270		
Cys	Asp	Thr	Ala	Ala	Thr	His	Asp	Asp	Leu	Leu	Ser	Arg	Phe	Met	Arg
	275						280					285			
Lys	Gly	Ser	Tyr	Ser	Asp	Glu	Ser	Leu	Gln	His	Val	Ala	Leu	Asn	Phe
	290					295					300				
Ile	Leu	Ala	Gly	Arg	Asp	Thr	Ser	Ser	Val	Ala	Leu	Ser	Trp	Phe	Phe
305					310					315					320
Trp	Leu	Val	Ser	Thr	His	Pro	Ala	Val	Glu	Arg	Lys	Ile	Val	Arg	Glu
				325					330					335	
Leu	Cys	Ser	Val	Leu	Ala	Ala	Ser	Arg	Gly	Ala	His	Asp	Pro	Ala	Leu
			340					345					350		
Trp	Leu	Ala	Glu	Pro	Phe	Thr	Phe	Glu	Glu	Leu	Asp	Arg	Leu	Val	Tyr
	355						360					365			
Leu	Lys	Ala	Ala	Leu	Ser	Glu	Thr	Leu	Arg	Leu	Tyr	Pro	Ser	Val	Pro
	370					375					380				
Glu	Asp	Ser	Lys	His	Val	Val	Ala	Asp	Asp	Tyr	Leu	Pro	Asp	Gly	Thr
385					390					395					400
Phe	Val	Pro	Ala	Gly	Ser	Ser	Val	Thr	Tyr	Ser	Ile	Tyr	Ser	Ala	Gly
			405						410					415	
Arg	Met	Lys	Gly	Val	Trp	Gly	Glu	Asp	Cys	Leu	Glu	Phe	Arg	Pro	Glu
		420						425					430		
Arg	Trp	Leu	Ser	Ala	Asp	Gly	Thr	Lys	Phe	Glu	Gln	His	Asp	Ser	Tyr
	435						440					445			
Lys	Phe	Val	Ala	Phe	Asn	Ala	Gly	Pro	Arg	Val	Cys	Leu	Gly	Lys	Asp
	450					455					460				
Leu	Ala	Tyr	Leu	Gln	Met	Lys	Asn	Ile	Ala	Gly	Ser	Val	Leu	Leu	Arg
465				470					475						480
His	Arg	Leu	Thr	Val	Ala	Pro	Gly	His	Arg	Val	Glu	Gln	Lys	Met	Ser
			485					490						495	
Leu	Thr	Leu	Phe	Met	Lys	Gly	Gly	Leu	Arg	Met	Glu	Val	Arg	Pro	Arg

Glu	Thr	Thr	Leu	Thr	Ser	Ser	Met	Ala	His	Val	Asp	Gln	Tyr	Leu	Ala	
				245					250					255		
Ala	Val	Ile	Lys	Lys	Arg	Lys	Leu	Glu	Leu	Ala	Ala	Gly	Asn	Gly	Lys	
			260					265					270			
Cys	Asp	Thr	Ala	Ala	Thr	His	Asp	Asp	Leu	Leu	Ser	Arg	Phe	Met	Arg	
		275					280					285				
Lys	Gly	Ser	Tyr	Ser	Asp	Glu	Ser	Leu	Gln	His	Val	Ala	Leu	Asn	Phe	
	290				295						300					
Ile	Leu	Ala	Gly	Arg	Asp	Thr	Ser	Ser	Val	Ala	Leu	Ser	Trp	Phe	Phe	
305					310					315					320	
Trp	Leu	Val	Ser	Thr	His	Pro	Ala	Val	Glu	Arg	Lys	Ile	Val	Arg	Glu	
				325					330					335		
Leu	Cys	Ser	Val	Leu	Ala	Ala	Ser	Arg	Gly	Ala	His	Asp	Pro	Ala	Leu	
			340					345					350			
Trp	Leu	Ala	Glu	Pro	Phe	Thr	Phe	Glu	Glu	Leu	Asp	Arg	Leu	Val	Tyr	
		355					360					365				
Leu	Lys	Ala	Ala	Leu	Ser	Glu	Thr	Leu	Arg	Leu	Tyr	Pro	Ser	Val	Pro	
	370					375					380					
Glu	Asp	Ser	Lys	His	Val	Val	Ala	Asp	Asp	Tyr	Leu	Pro	Asp	Gly	Thr	
385					390					395					400	
Phe	Val	Pro	Ala	Gly	Ser	Ser	Val	Thr	Tyr	Ser	Ile	Tyr	Ser	Ala	Gly	
				405					410					415		
Arg	Met	Lys	Gly	Val	Trp	Gly	Glu	Asp	Cys	Leu	Glu	Phe	Arg	Pro	Glu	
			420					425					430			
Arg	Trp	Leu	Ser	Ala	Asp	Gly	Thr	Lys	Phe	Glu	Gln	His	Asp	Ser	Tyr	
		435					440						445			
Lys	Phe	Val	Ala	Phe	Asn	Ala	Gly	Pro	Arg	Val	Cys	Leu	Gly	Lys	Asp	
	450					455					460					
Leu	Ala	Tyr	Leu	Gln	Met	Lys	Asn	Ile	Ala	Gly	Ser	Val	Leu	Leu	Arg	
465					470					475					480	
His	Arg	Leu	Thr	Val	Ala	Pro	Gly	His	Arg	Val	Glu	Gln	Lys	Met	Ser	
				485					490					495		
Leu	Thr	Leu	Phe	Met	Lys	Gly	Gly	Leu	Arg	Met	Glu	Val	Arg	Pro	Arg	
			500					505					510			
Asp	Leu	Ala	Pro	Val	Leu	Asp	Glu	Pro	Cys	Gly	Leu	Asp	Ala	Gly	Ala	
		515					520					525				
Ala	Thr	Ala	Ala	Ala	Ala	Ser	Ala	Thr	Ala	Pro	Cys	Ala				
	530					535					540					